Introduction {#s1}
============

The concept of an optimal protein concentration and its associated regulatory mechanisms is known as 'proteostasis'. While many studies have focused on proteostatic regulators that are associated with the proper synthesis, folding and elimination of protein aggregation ([@bib37]), less attention has been paid to the coordination of protein synthesis and degradation within cells. The study of proteostasis is particularly important in neurons because alterations in protein synthesis and degradation, particularly via the ubiquitin proteasome system (UPS), have emerged as network hubs in many disease states ([@bib15]; [@bib38]; [@bib56]).

As an additional challenge, neurons must dynamically regulate the synaptic proteome in response to plasticity elicited by neural activity. Many studies have demonstrated that de novo protein synthesis plays an important role in synaptic transmission and plasticity, ([@bib28]; [@bib55]). In addition, protein degradation, mediated by the ubiquitin proteasome system (UPS), also plays an important role in regulating synaptic function ([@bib5]; [@bib56]; [@bib46]). In neurons, proteome regulation occurs in the cell body as well as the dendrites and axons allowing the initiation of proteome remodeling at synapses, far from the cell body ([@bib28]). While it is clear that changes in synaptic transmission involve extensive regulation of the synaptic proteome via the regulated synthesis and degradation of proteins, it is not well understood how these two processes are coordinately regulated to achieve the desired level of individual proteins at synapses.

To address this question, we studied the impact of proteasome inhibition on protein synthesis in mature neurons. We found that blocking proteasome function leads to a coordinate reduction in protein synthesis, indicating the existence of a global proteostatic pathway in neurons. The entry point for down-regulation of protein synthesis is the much-studied protein synthesis initiation factor, eIF2α ([@bib20]). The phosphorylation of eIF2α that leads to reduced neuronal translation is accomplished by one of the eIF2α kinases, heme-regulated inhibitory kinase (HRI), best known for its translational control in erythrocyte precursors. The activity and expression of neuronal HRI is regulated in a biologically clever manner, expression is kept low by a short- half-life and a translational control mechanism that is relieved by proteasome inhibition- augmenting HRI expression and leading to the coordinate regulation of protein synthesis.

Results {#s2}
=======

Neuronal proteasome inhibition leads to a coordinate reduction in neuronal protein synthesis, globally and locally in dendrites {#s2-1}
-------------------------------------------------------------------------------------------------------------------------------

To determine whether the processes of neuronal protein synthesis and degradation are coupled, we examined the effect of blocking proteasomal degradation on nascent protein synthesis in cultured hippocampal neurons ([Figure 1A](#fig1){ref-type="fig"}). Blocking proteasome activity with either of two chemically distinct inhibitors (MG-132, 10 μM; Lactacystin, 10 μM; [Figure 1A--E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A--F](#fig1s1){ref-type="fig"}) for 2 hr led to a dramatic decrease in protein synthesis, measured with two different labeling methods: the non-canonical amino acid azidohomoalanine (AHA) and BONCAT (biorthogonal non-canonical amino acid tagging) ([@bib18]; [Figure 1B--C](#fig1){ref-type="fig"}) or metabolic labeling with puromycin ([Figure 1D,E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). The compensatory proteostatic decrease in protein synthesis did not require a complete block of proteasomal activity: dose-dependent reductions in proteasome activity led to coordinate reductions in protein synthesis ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). These data suggest that cross-talk can occur between the protein degradation and synthesis pathways in response to relatively small fluctuations in proteasome activity.

![Proteasome inhibition leads to a coordinate inhibition of protein synthesis in neurons.\
(**A**) Scheme indicating experimental protocol: cultured hippocampal neurons were exposed to a proteasome inhibitor (PI; MG132 or lactacystin- see supplementary figs) for 2 hr and then the non-canonical amino acid AHA was added for 10 min to label newly synthesized proteins (see Materials and methods). (**B**) Representative BONCAT western blot using an anti-biotin antibody to detect newly synthesized proteins (labeled with AHA and then clicked with a biotin alkyne tag). Shown are two biological replicates each from a control sample (not treated with a PI) and a PI-treated sample, respectively. (**C**) Analysis of experiment shown in B. Protein synthesis in hippocampal neurons was significantly reduced following proteasome inhibition. p\<0.001, unpaired t-test, three experiments. Error bars = SD. (**D**) Analysis of newly synthesized proteins (puromycylation; bar graphs) and K48 ubiquitin chains (line graph) after treatment of cultured neurons with 5, 10 or 20 μM Lactacystin. t-Test (multiple comparisons) n = 4 experiments for each concentration. For protein synthesis, 0 vs 5 μM p\<0.05, 0 vs 10 μM p \<0.01, 0 vs 20 μM p\<0.01, For K48 ubiquitin, 0 vs 5 μM p\<0.01, 0 vs 10 μM p \<0.001, 0 vs 20 μM p\<0.01. (**E**) Metabolic labeling (magenta; using puromycylation, see Materials and methods) of the global nascent protein pool in hippocampal cell bodies and dendrites following proteasome inhibition, nucleus (DAPI, blue) and dendrites (MAP2, green) can also be visualized in the images. Scale bar = 50 microns. (**F**) Analysis of protein synthesis (using puromycylation) of the global nascent protein pool in hippocampal neurons transfected with HA-Ubiquitin K48R+G76A --see [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, (unpaired t-tests p\<0.01, three experiments, n = 110 mock n = 105 ubi-K48R+G76A-transfected neurons). (**G**) Scheme of experiment to determine whether dendritic protein synthesis is also altered, neurons were treated with PI and labeled with AHA for the last 5 min. (**H**) Scheme of the experimental set up, neurons were cultured on a special membrane that allows dendrites and axons, but not cell bodies, to grow through pores. The proteasome was inhibited, then the cell bodies were scraped away from the top of the membrane and metabolic labeling was conducted on the dendritic fraction. (**I**) Inhibition of the proteasome results in a coordinate inhibition of dendritic protein synthesis. Representative BONCAT western blot showing the metabolically labeled newly synthesized dendritic protein in green. (**J**) Analysis of experiment shown in (**I**). Protein synthesis in dendrites was significantly reduced by over 60% following proteasome blockade, (p\<0.001, unpaired t-test, four experiments) Error bars = SEM. Molecular weight markers in B and G from top-to-bottom are 250, 150, 100, 75, 50, 37, and 25 kD.\
Figure 1---source data 1.Source data for [Figure 1A and G](#fig1){ref-type="fig"}.\
Figure 1---source data 2.Source data for [Figure 1C, D, F, J](#fig1){ref-type="fig"}.](elife-52714-fig1){#fig1}

Because cultured brain preparations contain a mix of neuronal and glial cell types, we also visualized protein synthesis, in situ, using puromycylation to detect protein synthesis ([@bib50]). In neurons, we observed that proteasome inhibition led to a decrease in protein synthesis apparent in both the cell bodies and dendrites of neurons ([Figure 1E](#fig1){ref-type="fig"}). The reduction in protein synthesis was not due to cell death ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}) or compromised cell health as protein synthesis levels were restored following an extensive (14 hr) washout of the proteasome inhibitor ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2B--D](#fig1s2){ref-type="fig"}). Furthermore, the overexpression of a mutant ubiquitin molecule, K48R+G76A (which inhibits polyubiquitination and is resistant to deubiquitinases thus inhibiting protein degradation by the proteasome \[[@bib27]; [@bib34]; [@bib35]\] also decreased protein synthesis ([Figure 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2,E--F](#fig1s2){ref-type="fig"}).

To determine if the proteostatic mechanism also functions in neuronal processes, we used a special membrane which separates neuronal cell bodies from dendrites and axons ('neurites') (see Materials and methods). We added a proteasome inhibitor for 2 hr, then physically removed the cell bodies from the region above the membrane and performed a brief (5 min) metabolic labeling (using AHA and BONCAT) on the isolated dendrites and axons inhabiting the region below the membrane ([Figure 1G,H](#fig1){ref-type="fig"}). We found that protein synthesis in neurites was also significantly inhibited by proteasome inhibition ([Figure 1I,J](#fig1){ref-type="fig"}), indicating that the feedback mechanism coupling protein degradation to synthesis also functions locally in neuronal processes.

Phosphorylation of the initiation factor eIF2α by HRI is responsible for reduced neuronal protein synthesis following proteasome inhibition {#s2-2}
-------------------------------------------------------------------------------------------------------------------------------------------

To determine the mechanisms by which protein synthesis is reduced, we first asked whether proteasome inhibition brings about a reduction in protein synthesis by altering transcription. Blocking transcription during proteasome inhibition, however, did not affect the reduction in protein synthesis we previously observed ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}). Because proteasome activity can contribute to amino acid recycling in cells, we measured the free amino acid content of the neurons, and we did not find any changes following proteasome inhibition ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). We thus focused on protein synthesis directly and examined the phosphorylation status, following proteasome inhibition, of several canonical translation factors known to influence protein synthesis initiation and elongation rates. The translation factors eIF4B, eIF4EBP1/2, and eIF4G showed no change in phosphorylation ([Figure 2---figure supplement 1D--E](#fig2s1){ref-type="fig"}). In contrast, as has been observed in mouse embryonic fibroblasts and other cell types ([@bib21]; [@bib33]; [@bib41]; [@bib43]; [@bib63]; [@bib66]; [@bib68]), we observed a marked and rapid increase in the phosphorylation of eIF2α (a key regulator of translation initiation) ([@bib25]), without a change in total eIF2α levels ([Figure 2A--C](#fig2){ref-type="fig"}). Consistent with a causal role of eIF2α phosphorylation in the inhibition of neuronal protein synthesis, we found that treatment with the integrated stress response inhibitor (that acts downstream of peIF2α) (ISRIB; \[[@bib53]\]) reversed the effects of proteasomal inhibition on protein synthesis ([Figure 2D,E](#fig2){ref-type="fig"}), without affecting basal levels of translation ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}).

![Reduced protein synthesis is mediated by eIF2α phosphorylation.\
(**A**) Scheme indicating experimental protocol: cultured hippocampal neurons were treated with a proteasome inhibitor (PI) and collected at the indicated time points. (**B**) Representative western blot showing the levels of phosphorylated (detected using a phospho-specific anti-eIF2α antibody) and total eIF2α under control conditions (t = 0) or following the indicated minutes of proteasome inhibition. (**C**) Analysis of experiments shown in B. PI treatment led to a significant increase in peIF2α levels. (unpaired t-test control vs each time point, Control vs 15 min p\>0.05, control vs 30 min p\<0.05, control vs 40 min p≤0.01, control vs 60 min p≤0.0001, control vs 120 min p≤0.01. (3 experiments). Error bars = SD. (**D**) Representative BONCAT western blot showing the metabolically labeled newly synthesized protein in green. Treatment with the small molecule inhibitor ISRIB rescued the PI-induced decrease in protein synthesis (2 hr of treatment). Molecular weight markers from top-to-bottom are 250, 150, 100, 75, 50, 37, 25, and 20 kD. Histone 3is shown as a loading control. (**E**) Analysis of experiment shown in D. The PI-induced protein synthesis inhibition (control vs. PI: p≤0.05) was rescued by ISRIB treatment (control vs. ISRIB, p\>0.05, unpaired t-test), four experiments, Error bars = SD.\
Figure 2---source data 1.Source data for [Figure 2A-B, D](#fig2){ref-type="fig"}.\
Figure 2---source data 2.Source data for [Figure 2C, E](#fig2){ref-type="fig"}.](elife-52714-fig2){#fig2}

There are four kinases that are known to phosphorylate eIF2α, the eIF2α kinases 1--4, commonly known as PERK (PKR-like ER kinase), PKR (protein kinase double-stranded RNA-dependent), GCN2 (general control non-derepressible-2), and HRI (heme-regulated inhibitor) ([@bib20]; [@bib57]). In order to evaluate which kinase (or kinases) phosphorylates eIF2α in response to proteasome inhibition, we first focused on GCN2 since it is well-established as a regulator of translation in neurons during synaptic plasticity ([@bib16]; [@bib59]), and was previously described to be activated in response to proteasome inhibitors in *D. melanogaster* ([@bib54]). Using cultured neurons from GCN2 knock-out mice we examined the sensitivity of protein synthesis to proteasomal inhibition. Surprisingly, in the absence of GCN2 protein synthesis was still inhibited by proteasome blockade ([Figure 3A](#fig3){ref-type="fig"}). We conducted the same experiments in cultured neurons obtained from PERK knock-out mice or in PKR-inhibited neurons and again observed no effect on the proteasome-dependent inhibition of protein synthesis ([Figure 3A](#fig3){ref-type="fig"}). We thus turned our attention to the least likely candidate, HRI, a kinase that is primarily activated by reduced cellular heme levels and is known to play an important role in regulating globin translation in erythrocytes ([@bib24]). Using neurons from an HRI knock-out mouse ([@bib24]) we observed a dramatically reduced inhibition of protein synthesis induced by proteasome blockade with metabolic labeling detected by western blot ([Figure 3B,C](#fig3){ref-type="fig"}) or in situ labeling of cultured hippocampal neurons ([Figure 3D,E](#fig3){ref-type="fig"}). HRI deletion had no effect on the basal levels of protein synthesis in neurons or in brain tissue ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). The absence of HRI also significantly reduced the proteasome inhibition-induced increase in eIF2α phosphorylation ([Figure 3F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), while the absence or inhibition of the other eIF2α kinases did not ([Figure 3---figure supplement 1D,E](#fig3s1){ref-type="fig"}). These data show that a kinase, known primarily for its translational regulatory role in erythrocytes, plays a critical role in neuronal proteostasis.

![HRI kinase is responsible for the proteasome-inhibition induced increases in eIF2α phosphorylation.\
(**A**) Genetic deletion (KO) or inhibition of the eIF2α kinases GCN2, PERK or PKR did not rescue the inhibition of protein synthesis elicited by proteasome inhibition. (wt vs. kinase KO or inhibition: GCN2, unpaired t-test p≤0.0001, PERK, unpaired t-test p≤0.001 and PKR p≤0.01, respectively, n = 2 experiments, two biological replicates per KO). Error bars = SD. (**B**) Representative puromycylation western blot showing that genetic deletion of HRI kinase rescues the inhibition of protein synthesis. Molecular weight markers from top-to-bottom are 250, 150, 100, 75, 50, 37, 25, 20, and 15 kD. (**C**) Analysis of the experiment shown in B. The amount of PI-induced protein synthesis inhibition was significantly reduced in the HRI KO (unpaired t-test on wt PI vs KO. PI p≤0.0001, wt control vs. PI p≤0.0001, KO. control vs. PI p≤0.05, n = 5 experiments, error bars SD. (**D**) Metabolic labeling (magenta; using puromycylation, see Materials and methods) of the global nascent protein pool in cultured hippocampal neurons following proteasome inhibition showing that HRI KO neurons exhibit less PI-induced inhibition of protein synthesis. Scale bar = 100 μm. (**E**) Analysis of experiments like that shown in D. Protein synthesis in hippocampal neurons was significantly reduced in the HRI KO following proteasome inhibition (unpaired t-test on wt control vs. k.o. control p\>0.05, wt PI vs k.o. PI p≤0.01, wt control vs. PI p≤0.0001, KO control vs. PI p≤0.05. n = 3 experiments, wt control n = 1104, wt-PI n = 955, ko control = 1457, ko-PI n = 1052 neurons). (**F**) Analysis of eIF2α phosphorylation in response to proteasome inhibition. PI treatment led to a significant increase in peIF2α levels. (unpaired t-test on wt control vs. PI: p≤0.01, t-test on HRI KO control vs. PI: p≤0.05. two experiments --see [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}. (**G**) RNA-seq data from hippocampal slices indicate that HRI mRNA is the most abundant amongst the 4 eIF2α kinases (**H**) Representative fluorescence in situ hybridization image detecting HRI mRNA in neuronal somata and dendrites. Scale bar = 20 μm for somata and 10 µm for dendrites-See [Figure 3---figure supplement 2A--D](#fig3s2){ref-type="fig"}.\
Figure 3---source data 1.Source data for [Figure 3B](#fig3){ref-type="fig"}.\
Figure 3---source data 2.Source data for [Figure 3A, C, E, F](#fig3){ref-type="fig"}.](elife-52714-fig3){#fig3}

HRI protein is expressed at vanishingly low levels in neurons under control conditions {#s2-3}
--------------------------------------------------------------------------------------

Given the surprising involvement of HRI, we next sought to measure the expression of HRI mRNA and protein in hippocampal neurons. Using data from a recent RNA-sequencing study ([@bib60]) we found that the HRI transcript is the most abundant of the 4 eIF2α kinases ([Figure 3G](#fig3){ref-type="fig"}) in hippocampal neurons. We used fluorescence in situ hybridization to validate and localize HRI mRNA in hippocampal neurons and tissue, and detected it in both somata and dendrites ([Figure 3H](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A--D](#fig3s2){ref-type="fig"}). The use of HRI knock-out tissue allowed us to identify in neurons, after immunoprecipitation, an HRI-specific band with one antibody ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). We observed that the HRI expression level in brain was very low compared to the HRI levels detected in heme-rich tissues like liver or blood ([Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}).

We next considered whether proteasome inhibition might boost HRI expression by altering the level of HRI mRNA or protein. Quantification of HRI mRNA using droplet digital PCR (ddPCR) revealed no change in HRI mRNA levels following 2 hr of proteasome inhibition ([Figure 4A](#fig4){ref-type="fig"}), consistent with the transcription-independence of the protein synthesis reduction elicited by proteasome inhibition ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Following treatment with a proteasome inhibitor for 2 hr there was, however, a significant upregulation in neuronal HRI protein levels ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}), suggesting that HRI might be a proteasome substrate. Although we were unable to detect appreciable polyubiquitylation of HRI (data not shown), using an in vitro assay with purified 20S proteasome and recombinant HRI we observed that HRI was degraded by the proteasome ([Figure 4---figure supplement 1E,F](#fig4s1){ref-type="fig"}).

![HRI exhibits low expression under basal conditions and increased expression following proteasome inhibition.\
(**A**) Analysis for ddPCR experiments showing there is no change in HRI mRNA level following proteasome inhibition, control vs. PI, (unpaired t-test, p\>0.05 n=3, error bars = SD). Samples were normalized to ribosomal RNA. (**B**) Quantification of immunoprecipitated HRI protein levels under control conditions or after proteasome inhibition (PI). After PI (2 hr) a significant increase in HRI protein was detected in PI samples vs. control, experiments are normalized to the untreated condition (unpaired t-test p≤0.0001, n = 4 experiments, error bars = SD). (**C**) Scheme showing the experimental procedure, cultured neurons were labeled with S^35^-Met for 2 hr, washed and collected after 2 and 4 hr + / - PI. (**D**) Analysis of immunoprecipitated and radiolabeled HRI. Under basal conditions the HRI half-life is ≈4 hr, its degradation is blocked by PI (unpaired t-test, 2 hr control vs PI p≤0.05, 4 hr control vs PI p≤0.05, four experiments, error bars = SD). (**E**) Scheme showing the doxycycline-inducible expression of the HA-tagged HRI protein. (**F**) Representative images of transfected neurons (arrowheads) with the bi-directional reporter resulting in robust expression of ZsGreen (green) but near absent expression of HRI (white) in the same population of cells. Also shown are somata and dendrites (labeled with an anti-MAP2 antibody). Scale bar = 50 μm. (**G**) Analysis of experiments in F, showing the correlation between ZsGreen fluorescence and HA (HRI) immunolabeling in individual neurons. Dotted horizontal lines indicate the area containing 90% of the HA immunofluorescence values of ZsGreen-negative (non-transfected) neurons (5--95% percentiles), the dotted vertical line indicates the threshold between ZsGreen-negative and ZsGreen positive cells. Grey dots represent ZsGreen-negative cells, magenta dots show neurons positive for ZsGreen but negative for HA, and green dots represent neurons positive for ZsGreen and above the HA 95% percentile of the ZsGreen-negative population (n = 149). See [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}.\
Figure 4---source data 1.Source data for [Figure 4A, B, D, G](#fig4){ref-type="fig"}.](elife-52714-fig4){#fig4}

The observation that HRI is a proteasome substrate suggests that proteasome inhibition stabilizes HRI protein levels. To estimate the magnitude of this effect, we metabolically pulse-labeled cultured neurons with ^S35^Methionine and immunoprecipitated HRI at different chase times under control and proteasome inhibition conditions. Surprisingly, we observed that HRI protein has an extremely short half-life under control conditions (\~4.2 hr). In addition, the short-lived HRI protein was significantly stabilized by proteasome inhibition ([Figure 4C,D](#fig4){ref-type="fig"}). These data indicate that inhibition of the proteasome alone is sufficient to augment HRI protein levels and can account for at least part of the increase in HRI protein expression.

To explore the possibility that there is translational regulation of HRI, we placed both a fluorescent reporter (ZsGreen) and a HA-tagged HRI protein in a single doxycycline (DOX)-inducible bi-directional plasmid ([Figure 4E](#fig4){ref-type="fig"}). Transfection of the plasmid into neurons or HeLa cells followed by DOX treatment led to robust expression of ZsGreen in a large population of cells whereas the expression of HRI was absent or barely detectable in the same population ([Figure 4F,G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2A--C](#fig4s2){ref-type="fig"}). This result was unexpected, given that the use of a bi-directional promoter typically results in roughly equal populations of expressed proteins ([@bib64]). We next considered the possibility that the mismatch of ZsGreen and HRI-HA expression could be due to the compromised translation of HRI-HA. To address how HRI translation behaves relative to global translation, we used polysome profiling, comparing control and proteasome inhibitor-treated hippocampal cultured neurons. As shown in [Figure 5A](#fig5){ref-type="fig"} and consistent with the relative inhibition of translation observed in [Figure 1](#fig1){ref-type="fig"}, we observed a leftward shift in the translational profile from polysomes to monosomes following proteasome inhibition. We confirmed this shift using ddPCR to detect beta-actin mRNA levels in each fraction in control and PI conditions ([Figure 5B](#fig5){ref-type="fig"}). In contrast, HRI mRNA did not exhibit a leftward shift after proteasome inhibition, but rather exhibited a paradoxical rightward shift to the polysomal fractions ([Figure 5C](#fig5){ref-type="fig"}). An increase in polysome occupancy after proteasome inhibition has also been observed for a stress-related transcript ([@bib58]; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) which exhibit aberrant increases in translation, caused by a variety of manipulations, that are often mediated by uORFs or IRES sequences ([@bib17]; [@bib39]). HRI, however, has a very short 5'UTR and no uORF or IRES is predicted ([@bib17]; [@bib42]; [@bib65]).

![HRI exhibits a codon-dependent paradoxical shift to enhanced translation following proteasome inhibition.\
(**A**) Representative polysome profile showing the effect of proteasome inhibition on translation. PI led to a dramatic shift to the monosome fraction, reflecting reduced global translation. (**B**) Quantification of ddPCR experiments examining the abundance of actin mRNA in monosomes and polysomes, normalized to control levels. Following PI, actin mRNA exhibited the typical shift to the monosome fraction (unpaired t-test, p≤0.05, n = 2 experiments (three technical replicates per experiment). (**C**) Quantification of ddPCR experiments examining the abundance of HRI mRNA in monosomes and polysomes, normalized to control levels. Unlike the global RNA population, HRI mRNA exhibited a significant shift to the polysome fraction following PI, (unpaired t-test, p≤0.05, n = 2 experiments three technical replicates). Error bars = SD. (**D**) Scheme of the HRI protein showing an abundance of many rare and extremely rare codons, consistent with HRI's extremely low level of translation under basal conditions in neurons. HRI uses more rare codons than the 86.78% of the genes expressed in the brain (see Materials and methods). (**E**) Representative images showing the increased expression of codon-optimized HRI-HA in comparison with HRI-wt (Scale bar = 100 μm). (**F**) Scheme showing the plasmids used for the transfection shown in E, the plasmid shown in the [Figure 4E](#fig4){ref-type="fig"} was split in two parts, one expressing ZsGreen and another one expressing HRI, the plasmids were transfected in 1:5 ratio (ZsGreen:HRI) (**G**) Analysis of the experiments in E, showing the correlation between ZsGreen fluorescence and HA immunolabeling in individual neurons from dishes co-transfected with ZsGreen and HRI-HA either as wt sequence (HRI-HA) or codon optimized (HRIopt-HA). Dotted horizontal lines indicate the area containing 90% of the HA immunofluorescence values of ZsGreen-negative (non-transfected) neurons of the HRI-HA transfections (5--95% percentiles), the dotted vertical line indicates the threshold between ZsGreen-negative and ZsGreen positive cells. Grey and black dots are represent ZsGreen-negative (non-transfected) neurons from dishes co-transfected with HRI-HA and HRI-opt-HA, respectively. ZsGreen-positive neurons from dishes co-transfected with HRI-HA are shown in green and from dishes co-transfected with HRIopt-HA are represented in magenta. Neurons positive for ZsGreen and HA are located in the upper right quadrant (n = 2484 neurons).\
Figure 5---source data 1.Source data for [Figure 5B, C, G](#fig5){ref-type="fig"}.](elife-52714-fig5){#fig5}

An alternative mechanism we considered for the low basal levels of HRI protein is the presence of rare codons in the protein coding sequence ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), which can result in reduced translational efficiency ([@bib9]; [@bib14]; [@bib22]; [@bib70]). We evaluated the rodent HRI sequence for the presence of rare codons and found a number of rare and extremely rare codons, HRI uses more rare codons than 86.78% of the genes expressed in the hippocampus (see Materials and methods), predicting compromised translation ([Figure 5D](#fig5){ref-type="fig"}). Indeed, when we expressed an HA-tagged HRI with optimized codon usage (HRI~opt~-HA) we observed that the basal expression of HRI~opt~-HA was higher ([Figure 5E,G](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) and HRI~opt~-HA exhibited a reduced rightward shift to the polysome fraction following treatment with a proteasome inhibitor ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Taken together these data indicate that HRI protein expression is paradoxically enhanced under conditions in which global protein synthesis is reduced. Two complementary mechanisms act to enhance HRI levels; first, a stabilization of the protein via reduced degradation by the proteasome and, second, enhanced translation owing to the increased availability of rare codons.

Stabilized HRI is constitutively active in neurons {#s2-4}
--------------------------------------------------

In erythrocyte precursors, HRI kinase is activated by multiple mechanisms, including an increase in reactive oxygen species (ROS) or nitric oxide (NO) or reductions in cellular heme ([@bib12]; [@bib13]; [@bib11]; [@bib31]; [@bib62]). Increases in ROS have been reported following proteasome inhibition ([@bib19]). We thus tested whether the HRI activation that follows proteasome inhibition is due to increases in either ROS or NO by quenching ROS or blocking NO synthesis during MG132 treatment. We found that neither ROS scavengers nor NO synthase inhibitors prevented the proteasome inhibitor-induced decreases in protein synthesis ([Figure 5---figure supplement 2A--E](#fig5s2){ref-type="fig"}). We then examined whether heme metabolism drives the activation of HRI. The major enzymatic path that promotes the breakdown of heme are the heme oxygenases (HO1 and 2). Treatment with two different heme oxygenase inhibitors, however, also failed to affect the protein synthesis reduction elicited by proteasome inhibition ([Figure 5---figure supplement 2F,G](#fig5s2){ref-type="fig"}). These data suggest that enhanced heme breakdown, per se, is not responsible for HRI activation.

In erythryocytes, HRI is activated by reductions in cellular heme levels. We next considered the possibility that basal heme levels might be low in neurons, relative to erythrocytes, which could lead to constitutive kinase activity. We directly measured free heme in neurons and blood and found that while blood had predictably high levels of free heme, heme could not even be detected in cultured hippocampal neurons, and total hippocampal lysates exhibited heme levels orders of magnitude lower than blood (hippocampus; 36 ± 8 fmol/μg, blood; 126 ± 18 pmol/μg). We next tested if the measured amount of heme in blood could indeed inhibit HRI kinase activity in an in vitro assay using recombinant HRI and its substrate eIF2α, together with ^32^P-ATP. We found that the addition of hemin (heme complexed with Fe^3+^) led to a significant reduction in eIF2α phosphorylation by HRI ([Figure 6A](#fig6){ref-type="fig"}). Given the clear heme-induced inhibition of HRI, we directly tested whether the cytoplasmic regulatory context for HRI is different in neurons by adding recombinant HRI and its substrate eIF2α, together with ^32^P-ATP to cellular lysates prepared from neurons or blood. We evaluated the phosphorylation of eIF2α and found that it was elevated in hippocampus when compared to blood, indicating that HRI is more active under basal conditions in the neuronal cytoplasmic context ([Figure 6B](#fig6){ref-type="fig"}). If the elevated HRI protein is constitutively active due to low neuronal heme levels, then the inhibition of protein synthesis induced by proteasome blockade should be amenable to rescue by exogenous heme in neurons. Indeed, we found that addition of hemin to cultured neurons resulted in a rescue of the protein synthesis inhibition ([Figure 6C](#fig6){ref-type="fig"}, [Figure 5---figure supplement 2H](#fig5s2){ref-type="fig"}), and a reduction in the phosphorylation levels of eIF2α ([Figure 5---figure supplement 2I,J](#fig5s2){ref-type="fig"}) caused by proteasome blockade. The addition of Hemin to HRI k.o. primary neurons had no effect on basal protein synthesis, ruling out an off-target effect of hemin ([Figure 5---figure supplement 2K,L](#fig5s2){ref-type="fig"}). Taken together, these data indicate that relatively low cytoplasmic heme levels in neurons favor the constitutive activity of HRI.

![HRI activity is constitutive owing to a low heme content in neurons.\
(**A**) In vitro eIF2α phosphorylation assay by HRI; 100 and 200 pm of hemin were added to the reaction mixture (500 ng eIF2α and 3,3 ng of HRI), inhibiting the activity of the kinase (unpaired t-test control vs hemin 100pm p≤0.0001, control vs hemin 200pm p≤0.01). (**B**) In vitro eIF2α phosphorylation assay by HRI; a constant amount of eIF2α was added for each reaction combined with increasing amounts of HRI as indicated (See Materials and methods). Increasing amounts of HRI protein lead to significantly higher levels of eIF2α phosphorylation in hippocampal lysates, compared to blood lysates (the lysates were cleared of protein by heating 10 min at 60**°**C) (unpaired t-test 0.05 ng HRI Blood vs hippocampus p≥0.05, 0.1 ng HRI Blood vs hippocampus p≥0.05, 0.33 ng HRI Blood vs hippocampus p≤0.05, 66 ng HRI Blood vs hippocampus p≤0.05, n = 3 experiments). (**C**) Western blot analysis of experiments testing whether hemin (heme complexed with Fe^3+^) can mitigate the effects of PI. Hemin significantly reduced the PI-induced protein synthesis inhibition. (PI vs. control, p≤0.0001; PI vs. PI +hemin, p≤0.01 Error bars = SD, three experiments) (**D**) Representative images showing that HA-HRIexpressing neurons (arrow) (green; anti-HA labeling) exhibit lower levels of protein synthesis (magenta) when compared to neighboring neurons, which do not express HA-HRI. Also shown are somata and dendrites (labeled with an anti-MAP2 antibody) and nuclei (labeled with DAPI). Scale bar = 50 μm. (**E**) Quantification of somatic protein synthesis levels in neurons expressing or lacking HA-HRI; HA-HRI positive neurons exhibited significantly lower levels of protein synthesis, (p≤0.0001, HA negative neurons n = 852 and HA positive neurons n = 253, unpaired t-test).\
Figure 6---source data 1.Source data for [Figure 6A, B, C, E](#fig6){ref-type="fig"}.](elife-52714-fig6){#fig6}

The observation that the neuronal cytoplasmic context favors HRI activity suggests that mere expression of HRI could serve as a regulatory switch for protein synthesis. We revisited the HRI over-expression experiments to examine protein synthesis in neurons expressing HRI or not. Brief metabolic labeling of transfected neurons to measure protein synthesis indicated that the small neuronal population that expressed appreciable levels of HRI exhibited significantly reduced protein synthesis, on average, relative to other cells that did not express HRI ([Figure 6D,E](#fig6){ref-type="fig"}). Furthermore, small increases in HRI expression can have a significant impact on protein synthesis ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This indicates that, in neurons, the cytoplasmic environment is permissive for the constitutive activity of HRI upon expression. In addition, HRI's potent effect on global translation provides an explanation for why its expression is usually maintained at low levels in neurons. These features of HRI, its basal very low expression, its short half-life and the boost in protein levels upon proteasome inhibition, thus make it both an optimal sensor and effector for proteostasis during situations of compromised proteasome activity.

Discussion {#s3}
==========

Here we report that after brief period of proteasomal inhibition (via a pharmacological or genetic manipulation), neuronal protein synthesis is coordinately reduced via the actions of the eIF2α kinase 1, or heme-regulated inhibitor kinase. Taken together, our data indicate the following sequence of events unfolds to restore proteostasis: i) proteasome inhibition (PI) stabilizes the extremely short-lived neuronal HRI protein, ii) endogenous low levels of neuronal heme result in constitutive activation of HRI which increases the phosphorylation of eIF2α and reduces translation initiation, iii) the initial decrease in general translation may lead to an increase in the availability of charged rare tRNAs ([@bib48]), further increasing the translation of HRI mRNA and ensuring ongoing phosphorylation of eIF2α and as a result, reduced global translation.

The above-described mechanism allows for the coordination of protein synthesis and degradation in neurons, so that global protein levels stay balanced. We found that the same feedback mechanism can be detected in isolated neuronal processes, including dendrites and potentially axons. Local synthesis and degradation of proteins occurs in dendrites and axons via localized mRNAs, ribosomes and components of the UPS (e.g. \[[@bib5]; [@bib8]; [@bib23]; [@bib29]\]). It is not known, however, the spatial scale over which this proteostasis operates in axonal or dendritic compartments. In addition, a completely open question in all cells is the how proteostasis is accomplished at the level of individual proteins-of-interest.

Our data indicate that the above mechanisms cleverly cooperate to enhance the expression and activity of HRI in response to reduced proteasome activity. These mechanisms make HRI an optimized sensor and effector for sensing and responding to proteasome inhibition. In this regard, it is interesting to note that while the HRI transcript is detected at higher levels than the other 3 eIF2α kinases in hippocampal neurons, the HRI protein is expressed at very low levels under basal conditions, suggesting strong cellular pressure to keep HRI protein expression low. We observed, though, that HRI levels exhibit an increase upon proteasome inhibition, consistent with our observation that HRI can be degraded by the proteasome in vivo and in vitro. In addition, attempts to over-express HRI via transfection were largely thwarted. We evaluated the transcript for the presence of rare codons which can reduce translational efficiency (e.g. \[[@bib22]\]). Indeed, HRI mRNA possesses many rare and extremely rare codons; expression of a codon-optimized HRI resulted in higher levels of basal translation. In addition, in polysome profiling experiments, we found that HRI mRNA exhibited a paradoxical shift to the polysome fraction following proteasomal inhibition, while the bulk of cellular mRNAs exhibited a shift to the monosome fraction, consistent with their reduced global translation. Owing to the apparent absence of uORFs in the 5'UTR of HRI, we propose that rare codon availability could explain the atypical behavior of HRI mRNA following PI ([@bib48]), in support of this idea, the codon-optimized HRI failed to exhibit the shift to the polysome fraction upon PI.

In erythrocytes, HRI is activated by reduced heme levels to coordinately reduce the synthesis of α- and β-globin ([@bib24]); together α-globin, β-globin, and heme, assembled in a 2:2:4 ratio, make up hemoglobin. Getting the stoichiometry just right is important for red blood cells (RBCs) since an overabundance of any single component is cytotoxic to RBCs and their precursors. We found that heme levels are extremely low or undetectable in neurons, indicating that once expressed at appreciable levels, HRI will be constitutively active. Indeed, we observed significantly elevated HRI activity in a control hippocampal lysate when compared to a control blood lysate. Importantly and definitively, we observed that the PI-induced protein synthesis inhibition was rescued by the addition of hemin.

Taken together, multiple mechanisms act in concert to tightly control the dynamic range of HRI. Under control conditions HRI exhibits barely detectable levels of expression and activity due to its high turn-over and low translation rates. The inhibition of the proteasome is sensed by the stabilization of HRI and the low neuronal heme content means that HRI can respond immediately to the environment created by proteasome blockade. These data further suggest that physiological and pathophysiological conditions that give rise to proteasome dysfunction may favor HRI expression and activity leading to a decrease in protein synthesis.

The role of HRI as a primary mediator of the feedback between the degradation and protein synthesis machinery is surprising given the prominent role the other eIF2α kinases (GCN2, PERK and PKR) are known to play in neuronal translational regulation ([@bib6]; [@bib16]; [@bib30]). Indeed, all four of the eIF2α kinases have been associated with the phosphorylation of eIF2α in response to proteasome inhibition. These studies were performed with cell lines of non-neuronal origin or mouse embryonic fibroblasts (MEF) ([@bib33]; [@bib66]; [@bib68]). In addition, the activation of mTOR pathway following UPS inhibition has also been linked to a decrease in protein synthesis ([@bib69]). In our experiments, HRI is clearly the major kinase responsible for the proteasome inhibition-induced feedback regulation of neuronal protein synthesis; we think it is likely, however, that the other eIF2α kinases also play a role, potentially when HRI is absent or during periods of prolonged proteasome inhibition. Parsing the unique and complementary roles of these kinases will have to take into account the unique translation/degradation rates of each cell type together with the specific expression the eIF2α kinases, protein chaperones and heme content ([@bib61]).

We note that HRI's role in neuronal function is poorly explored, save for two reports of HRI influencing the translation of synaptic proteins ([@bib47]) and influencing learning ([@bib32]). In addition, the regulation by heme highlights an important element to consider in the context of neuronal function, given emerging data that point to dysregulation of iron homeostasis in disease ([@bib49]). Dysfunctional proteasome activity occupies a central position in many neurodegenerative diseases, and increased phosphorylation in eIF2α has been detected in postmortem brains of AD patients ([@bib10]). Prion infection also inhibits proteasomal activity and increases polyubiquitin levels by 2--3 times (similar to the levels observed in our conditions of study- see [Figure 1D](#fig1){ref-type="fig"}; [@bib36]). Strikingly, reperfusion after ischemic stroke leads to a profound proteasome inhibition in brain tissue ([@bib26]). In addition, in hemorrhagic strokes heme is liberated in the brain ([@bib3]; [@bib45]) and causes neuronal toxicity. The expression of HRI in neurons and its susceptibility to heme regulation should thus be considered in the realms of neurodegeneration and iron dyshomeostasis.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource               Designation                                                          Source or reference                                                        Identifiers                                                               Additional\
                                                                                                                                                                                                                                                                             information
  ------------------------------------------------ -------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Gene (Rat or Mouse)                              -HRI\                                                                GeneScript\                                                                Entrez Gene: NM_013557.2                                                  
                                                   -HRI-opt\                                                            Clone ID: OMu18622C                                                                                                                                  
                                                   -ZsGreen                                                                                                                                                                                                                  

  Strain, strain background (*Escherichia coli*)   BL21 (DE3)                                                           Sigma-Aldrich                                                              CMC0016                                                                   Electrocompetent cells

  Genetic reagent (Rat or Mouse)                   -Primary Neurons                                                     Other                                                                                                                                                Animals obtained from our animal house

  Cell line (Human)                                -HeLa (RRID:[CVCL_0030](https://scicrunch.org/resolver/CVCL_0030))   -ATCC                                                                                                                                                

  Transfected construct (mouse, Rat)               -HA-HRI\                                                             This paper                                                                                                                                           Constructs used to over-express HRI or ubiquitin genes in primary neurons.\
                                                   -HRI-HA\                                                                                                                                                                                                                  The constructs of HRI with the different tags can be obtained from Erin Schuman's Laboratory (MPI-BR)
                                                   -HRI-HA-opt\                                                                                                                                                                                                              
                                                   -ZsGreen\                                                                                                                                                                                                                 
                                                   -ZsGreen-HRI-HA\                                                                                                                                                                                                          
                                                   -Ubiquitin K48R                                                                                                                                                                                                           

  Biological sample (Mouse)                        -Blood (mouse wt and HRI K.O)\                                       DOI:\                                                                                                                                                
                                                   -Liver (mouse wt and HRI K.O)\                                       [10.1093/emboj/20.23.6909](https://doi.org/10.1093/emboj/20.23.6909)                                                                                 
                                                   -Brain (mouse wt and HRI K.O)                                                                                                                                                                                             

  Antibody                                         -Rabbit polyclonal anti-peIF2α                                       Invitrogen                                                                 44728G\                                                                   (1:1000) WB
                                                                                                                                                                                                   RRID:[AB_1500038](https://scicrunch.org/resolver/AB_1500038)              

  Antibody                                         -Mouse monoclonal eIF2α                                              Cell signalling                                                            2103                                                                      (1:1000) WB

  Antibody                                         -Rabbit polyclonal peIF4B                                            Cell signalling                                                            5399                                                                      (1:2000) WB

  Antibody                                         -Rabbit Monoclonal p4EBP1                                            Cell signalling                                                            2855\                                                                     (1:1000) WB
                                                                                                                                                                                                   RRID:[AB_560835](https://scicrunch.org/resolver/AB_560835)                

  Antibody                                         -Rabbit polyclonal peIF4G                                            Cell signalling                                                            2441                                                                      (1:25000) WB

  Antibody                                         -Rabbit polyclonal HRI                                               Millipore                                                                  07--728\                                                                  (1:1000) WB
                                                                                                                                                                                                   RRID:[AB_441964](https://scicrunch.org/resolver/AB_441964)                

  Aantibody                                        -Rabbit polyclonal anti-actin                                        abcam                                                                      Ab8227\                                                                   (1:5000) WB
                                                                                                                                                                                                   RRID:[AB_2305186](https://scicrunch.org/resolver/AB_2305186)              

  Antibody                                         -Rabbit polyclonal anti-H3                                           Abcam                                                                      AB18521\                                                                  (1:10000) WB
                                                                                                                                                                                                   RRID:[AB_732917](https://scicrunch.org/resolver/AB_732917)                

  Antibody                                         -Rabbit polyclonal anti-biotin                                       SIGMA                                                                      31852                                                                     (1:10000) WB

  Antibody                                         -Mouse monoclonal anti-puromycin                                     Kerafast                                                                   3RH11                                                                     (WB, 1:1000, IF 1:3500)

  Antibody                                         -Guinea pig polyclonal anti-MAP2                                     Synaptic Systems                                                           188004                                                                    (IF 1:1000)

  Antibody                                         -Rabbit polyclonal anti- HA-tag                                      Rockland                                                                   600-401-384                                                               (IF 1:2000)

  Antibody                                         -Goat polyclonal anti-mouse or anti-rabbit IR680 or IR800            Licor                                                                      -Goat anti-mouse or anti-rabbit IR680 or IR800                            (WB 1:5.000,)

  Antibody                                         -Goat polyclonal anti-guinea pig Dylight405                          Dianova                                                                    106-475-008\                                                              (IF 1:1000)
                                                                                                                                                                                                   RRID:[AB_2337434](https://scicrunch.org/resolver/AB_2337434)              

  Antibody                                         -Goat polyclonal anti-guinea pig-Alexa488                            Dianova                                                                    106-546-003\                                                              (IF 1:1000)
                                                                                                                                                                                                   RRID:[AB_2337441](https://scicrunch.org/resolver/AB_2337441)              

  Antibody                                         -Alexa488, polyclonal goat anti-rabbit Alexa647 or -Alexa546         ThermoFisher                                                               R37116, A32733, A-21085                                                   (IF all 1:1000)

  Peptide, recombinant protein                     -eIF2a\                                                              Abcam                                                                      ab95932\                                                                  
                                                   -HRI                                                                                                                                            ab131665                                                                  

  Peptide, recombinant protein                     −20S proteasome                                                      Enzo                                                                       BML-PW8720-0050                                                           

  Commercial assay or kit                          -Free heme measurement kit                                           Sigma                                                                      MAK316                                                                    

  Chemical compound, drug                          -Puromycin\                                                          Sigma                                                                      -Puromycin (P8833)\                                                       
                                                   -Doxycycline (Doxo)\                                                                                                                            -Doxycycline (D9891)\                                                     
                                                   -MG132\                                                                                                                                         -MG132 (M8699)\                                                           
                                                   -Lactacystin\                                                                                                                                   -Lactacystin (L6785)\                                                     
                                                   −7-Nitroindazole (7-NA)\                                                                                                                        −7-Nitroindazole (N7778)\                                                 
                                                   -S-methyl-L-thiocitrulline (L-SMTC)\                                                                                                            -S-methyl-L-thiocitrulline (M5171)\                                       
                                                   -N-acetyl-cysteine (NAC)\                                                                                                                       -N-acetyl-cysteine (A9165)\                                               
                                                   -Ascorbic Acid (AA)\                                                                                                                            -Ascorbic Acid (A1968)\                                                   
                                                   -MitoTempo\                                                                                                                                     -MitoTempo (SML0737)\                                                     
                                                   -Trolox\                                                                                                                                        -Trolox (648471)\                                                         
                                                   -Actinomycin-D (ActD)\                                                                                                                          -Actinomycin-D (A1410)\                                                   
                                                   -FePPIX (hemin)\                                                                                                                                -FePPIX (hemin) (H9039)\                                                  
                                                   -CoPPIX                                                                                                                                         -CoPPIX (C1900)                                                           

  Chemical compound, drug                          -SnMPIX\                                                             Cayman                                                                     -SnMPIX (19071)\                                                          
                                                   -ZnPPIX\                                                                                                                                        -ZnPPIX (14483)\                                                          
                                                   -NG mono methyl L-Arginine (L-NMMA)\                                                                                                            -L-NMMA (10005031)\                                                       
                                                   -The PKR inhibitor                                                                                                                              -The PKR inhibitor (15323)                                                

  Genetic reagent (*Mus musculus*)                 -PERK K.O.\                                                          Jackson                                                                    -PERK K.O. (line \#009340)\                                               
                                                   -GCN2 K.O.                                                                                                                                      RRID:[IMSR_JAX:009340](https://scicrunch.org/resolver/IMSR_JAX:009340)\   
                                                                                                                                                                                                   -GCN2 K.O. (line \#008240)\                                               
                                                                                                                                                                                                   RRID:[IMSR_JAX:008240](https://scicrunch.org/resolver/IMSR_JAX:008240)    

  Genetic reagent (*Mus musculus*)                 -HRI K.O.\                                                           PMID:[11726526](https://www.ncbi.nlm.nih.gov/pubmed/11726526) ([@bib24])                                                                             
                                                   Obtained from the laboratory of Dr, Jane Chen\                                                                                                                                                                            
                                                   (Harvard-MIT)                                                                                                                                                                                                             

  Software, algorithm                              <https://github.molgen.mpg.de/MPIBR-Bioinformatics/CodonUsage>       <https://github.molgen.mpg.de/MPIBR-Bioinformatics/CodonUsage>                                                                                       The kinase gene list was generated by a keyword search in gene description. Analysis and plotting scripts can be found in this repository

  Sequence-based reagent                           HRI Taqman Assay                                                     IDT                                                                        Rn.PT.58.5930825                                                          Used for ddPCR

  Sequence-based reagent                           Rn18s rRNA 18 s Taqman Assay                                         Thermo-fisher                                                              Mm0427757_s1                                                              Used for ddPCR

  Sequence-based reagent                           Actin beta Taqman Assay                                              IDT                                                                        Rn.PT.39a.22214838.g                                                      Used for ddPCR

  Sequence-based reagent                           Atf4 Taqman Assay                                                    IDT                                                                        Rn.PT.58.13690870.g                                                       Used for ddPCR

  Sequence-based reagent                           HRI-HA                                                               IDT                                                                        PCR primer one for\                                                       Used for ddPCR\
                                                                                                                                                                                                   HRI-hemagglutinin tag                                                     CAGCTACTGCAGAGCGAACT

  Sequence-based reagent                           HRI-HA                                                               IDT                                                                        PCR primer two for\                                                       Used for ddPCR\
                                                                                                                                                                                                   HRI-hemagglutinin tag                                                     GCGTAATCTGGAACATCGTATGG

  Sequence-based reagent                           HRI-HA                                                               IDT                                                                        Probe                                                                     Used for ddPCR\
                                                                                                                                                                                                                                                                             /56-FAM/AGCCTCCTT/ZEN/TCGCAGGACAAAGGGCTG/3IABkFQ/

  Sequence-based reagent                           HRI-HA-opt                                                           IDT                                                                        PCR primer 1 HRI-hemagglutinin tag optimized                              Used for ddPCR\
                                                                                                                                                                                                                                                                             TCCAGAGCGAGCTGTTCCAG

  Sequence-based reagent                           HRI-HA-opt                                                           IDT                                                                        PCR primer 2 HRI-hemagglutinin tag optimized                              Used for ddPCR\
                                                                                                                                                                                                                                                                             GCATAGTCAGGCACATCATAAGGG

  Sequence-based reagent                           HRI-HA-opt                                                           IDT                                                                        Probe\                                                                    Used for ddPCR\
                                                                                                                                                                                                   HRI-hemagglutinin tag optimized                                           /56-FAM/ACCACCGGC/ZEN/AACGTGAACCTGACCC/3IABkFQ/
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Primary neuronal cultures {#s4-1}
-------------------------

Neuronal cultures were prepared and maintained as described in [@bib1]. Briefly, the cortex from E17 mice or hippocampus from P1 rats were dissected, dissociated with papain (Sigma) and plated on poly-D-lysine coated dishes. Neurons were maintained at 37°C and 5% CO~2~ in Neurobasal-A plus B27 and GlutaMAX, (Life Technologies). One day after plating neurons were incubated with 3 µM AraC (Sigma) for two days, then the AraC was removed by changing the media. Unless otherwise indicated, neurons were used for experiments at DIV 14--21. For the experiments with KO mice cortical neurons were used, hippocampal neurons where used for the rest of the experiments.

Transgenic animals {#s4-2}
------------------

PERK KO (line \#009340) and GCN2 KO (line \#008240) mice were purchased from the Jackson laboratory. The HRI KO mouse line was kindly provided by Dr. Jane-Jane Chen ([@bib24]). All lines were maintained as heterozygotes. For neuron cultures, E17 pups from KO/WT x KO/WT breedings were genotyped as indicated by the manufacturer or ([@bib24]). Cortices from WT and KO animals were pooled separately and dissociated and plated as described above. Procedures involving animals were performed according to German and Max Planck Society animal care guidelines and approved by and reported to the local governmental supervising authorities (Regierungspräsidium Darmstadt).

Metabolic labeling, BONCAT and tissue preparation {#s4-3}
-------------------------------------------------

Neurons were grown and treated with various agents (proteasome inhibitors and other inhibitors) in Neurobasal A (Invitrogen). After treatment, the medium was changed to Neurobasal A lacking Methionine and supplemented with 4 mM AHA + / - treatments for 10 min. Neurons were washed 3x with PBS and lysed in PBS with 1% (w/v) Triton X100, 0.4% (w/v) SDS, protease inhibitors w/o EDTA (Calbiochem, 1:750) and benzonase (Sigma, 1:1000), heated at 95°C and centrifuged. BONCAT was performed as described in [@bib18]. In brief, 30 µg of total protein was subjected to a click reaction with 300 μM Triazol (Sigma, ref 678937), 50 μM biotin-alkyne tag (Thermo, ref B10185) and 83 μg/mL CuBr at 4°C o.n. in the dark. Biotinylated proteins were detected by Immunoblot. For puromycylation, puromycin was added to the culture media + / - treatments to a final concentration of 1.5 ng/µl for 10 min, then the neurons were washed 2x with PBS and lysed. For phosphorylation studies a phosphatase inhibitor cocktail (Invitrogen) was added to the lysis buffer. Tissue from HRI KO or wild-type mice was homogenized in lysis buffer (1% (w/v) Triton X100, 1% (w/v) SDS, protease inhibitors (1:750) and benzonase (1:500), heated to 95°C and centrifuged. SDS-PAGE was performed with 3 µg of lysate and proteins were subsequently blotted onto PVDF membranes.

Metabolic labeling of dendrites and axons (neurites) {#s4-4}
----------------------------------------------------

1 million dissociated rat hippocampal neurons were plated into 6-well filter inserts with a 3 µm pore size (Falcon). The day after plating AraC (3 µM; Sigma) was added to the cultures and medium was changed two days later. At DIV8 the proteasome inhibitor MG132 (10 µM) was added to the medium. After 2 hr of treatment the upper part of the filter was carefully scraped with PBS to remove the cell bodies. The dendrites and axons remaining on the other side of the filters were washed 3 times in Neurobasal A-lacking Methionine and incubated for 5 min in Neurobasal A-lacking Methionine supplemented with 4 mM AHA and MG132 (10 µM). Dendrites were collected in lysis buffer and BONCAT was performed as described above. For an example of the quality of compartment separation by the membranes see Figure S1 in [@bib4].

Cell viability {#s4-5}
--------------

Neurons were plated in 96 mw plates (20.000 neurons per well) and grown in Neurobasal A without phenol red. The viability was measured with a cell counting kit-8 (Sigma) following the manufacturer instructions. Cell counting solution was added to the media for 1 hr after 2 hr of PI incubation (3 hr of PI incubation in total).

In situ puromycylation, RNA-FISH and immunocytochemistry {#s4-6}
--------------------------------------------------------

In puromycylation experiments, rat hippocampal or mouse cortical neuron cultures grown on MatTek glass bottom dishes were treated ±proteasome inhibitors and other drugs for the indicated times before puromycin was added at a final concentration of 3.0 µM for 5 min then cells were washed 2 times with PBS-MC before fixation and immunocytochemistry. In FISH or immunocytochemistry experiments without puromycylation the incubation medium was removed and cells were immediately fixed for 20 min with PBS containing 4%Sucrose and 4%PFA, pH = 7.4. Panomics RNA-FISH was performed as described previously ([@bib7]) using the ViewRNA ISH Cell Assay Kit with 550 dye detection (ThermoFisher). For immunocytochemistry, cells were permeabilized for 15 min with 0.5% Triton in blocking buffer (BB) (PBS with 4% goat serum), blocked in BB for 1 hr and incubated with primary antibodies in BB for 1 hr. After washing, secondary antibodies in BB were applied for 30 min followed, when necessary, by a 3 min incubation with 1 µg/µl DAPI in PBS to stain nuclei. Cells were washed and imaged in PBS and mounted with Aquapolymount (Polysciences) for storage.

Proteasome peptidase activity {#s4-7}
-----------------------------

Proteasome activity was measured as described ([@bib40]). In brief, after treatment with proteasome inhibitors the neurons were washed 2x with cold PBS and lysed (50 mM Hepes pH 7.4, 50 mM NaCl, 5 mM EDTA, 10 µM leupeptin, 1 μg/ml pepstatin and 1 mM PMSF). Lysates were homogenized and centrifuged at 3000 g for 10 min at 4°C. Supernatants were immediately used for measurement of proteasome peptidase activity by cleavage of the fluorogenic peptide *N*-Suc-LLVY-MCA (Sigma), enzymatic activity were acquired for 2 hr. Fluorescence was detected in a micro-plate reader (TECAN) with 400/505 filters. To estimate background signal produced from cleavage by other proteases, proteasome inhibitors were added to lysates from untreated controls.

Antibodies {#s4-8}
----------

The following antibodies were used for immunofluorescence (IF) and/or immunoblotting (IB) at the indicated dilutions: Rabbit anti-peIF2α (for PLA 1:6000 \#44728G Invitrogen, and IB, 1:1000, Cell Signaling), mouse anti-eIF2α (IB, 1:1000, Cell Signaling). peIF4B, p4EBP1, peIF4G (IB:1:2500, cell signaling). Most of the commercially available antibodies that should recognize rodent HRI failed to robustly detect the protein in neurons. Nevertheless, the use of HRI knock-out tissue allowed us to identify in neurons, after immunoprecipitation, an HRI-specific band only with one HRI antibody: 07--728, Millipore. Rabbit anti-actin (1:5000, Abcam), rabbit anti-H3 (1:10000, Abcam) rabbit anti-biotin (IB, 1:1000), mouse anti-puromycin (IB, 1:1000, IF 1:3500, Kerafast,), guinea pig anti-MAP2 (IF 1:1000, Synaptic Systems), rabbit anti- HA-tag (IF 1:2000, Rockland) Goat anti-mouse or anti-rabbit IR680 or IR800 (IB, 1:5.000, Licor), goat anti-guinea pig Dylight405 (IF 1:1000, Dianova), goat anti-guinea pig-Alexa488, and goat anti mouse-Alexa546 or -Alexa488, goat anti-rabbit Alexa647 or -Alexa546 (IF all 1:1000, ThermoFisher).

Immunoprecipitation {#s4-9}
-------------------

The anti-HRI antibody was conjugated with Dynabeads (protein G, Invitrogen) o.n. at 4°C. 30 million mouse cortical neurons (DIV10) were used per IP reaction and lysed in 50 mM NaCl, 0.5% NP40 buffer. The lysate was centrifuged at 16,000 g for 15 min. The supernatant was incubated with the antibody-bound beads o.n. at 4°C. After binding, the beads were washed 4x times for 20 min with lysis buffer at 4°C. Bound proteins were eluted from the beads with 0.1M glycine pH = 2.5, the eluates neutralized, subjected to SDS-PAGE and transferred to PVDF membranes.

DNA constructs {#s4-10}
--------------

Rat HRI was cloned into the Tet on-off system from Clontech (Tet-On 3G Bidirectional Inducible Expression System with ZsGreen1) and an HA tag was added. For some experiments (as indicated in the text) ZsGreen sequences were removed from the plasmid (HRI-HA Tet-On minZsGreen) leaving only HRI and HA inserted (constructs synthesized by GenScript). Codon-optimized versions were made in HRI-HA Tet-On minZsGreen plasmids using GenScript algorithms including optimization of the HA tag. HA-Ubiquitin K48R-G76A (construct synthesized by GenScript).

Transfections {#s4-11}
-------------

Neurons were transfected with Magnetofectamine (Life Technologies) using 1.5 µg of DNA per 40K neurons for 1 hr in Neurobasal A (Invitrogen). After transfection, the transfection medium was replaced by conditioned medium. When the plasmid HRI-HA Tet-On minZsGreen was used (see constructs above), it was mixed in a 5:1 proportion with a plasmid containing only ZsGreen under the same bidirectional, inducible promoter to control for transfection efficiency (ten times excess of HRI-HA Tet-On minZsGreen). One week after transfection, Doxycycline (1 µg/1 µl, Invitrogen) was added to the cultures for 16 hr before puromycylation. HeLa cells (ATCC) were grown in Dulbecco\'s modified eagle\'s medium (DMEM, Invitrogen) with 10% fetal calf serum (FCS) at 37°C in an atmosphere with 5% CO~2~ and transfected with lipofectamine (Invitrogen) according to the manufacturer's instructions. Contamination with mycoplasma was evaluated by PCR (eMyco kit, Intron Biotechnology). After 24 hr of transfection Doxycycline was added and experiments were performed.

HRI codon usage {#s4-12}
---------------

A Codon adaptation index (CAI) ([@bib51]) was used to calculate the relative abundance of rare codons in HRI compared with both the transcripts expressed in the hippocampus (12643) and 566 kinases expressed in the hippocampus ([@bib44]). HRI has a lower CAI value than the median for all genes (median for EIF2αk1 = 0.7637 vs. all genes = 0.7995 or kinases = 0.8005) in both cases CAI value for EIF2αk1 is in the lowest quartile of the observed CAI distributions. Compared to the distributions EIF2αk1 has the following percentile: 1.) all genes =\> 13.2238 (EIF2αk1 uses more rare codons than 86.78% of the genes expressed in the hippocampus) 2.) all kinases =\> 9.5456 (EIF2αk1 uses more rare codons than 90.46% of the kinases expressed in the hippocampus). The mouse reference Transcriptome was downloaded from NCBI RefSeq repository (<ftp://ftp.ncbi.nlm.nih.gov/refseq/M_musculus/mRNA_Prot/>). Gene expression in mouse acute hippocampal slices in control conditions was determined by RNA sequencing experiment previously conducted in the lab ([@bib67]). The kinase gene list was generated by a keyword search in gene description. Analysis and plotting scripts can be found in the following repository <https://github.molgen.mpg.de/MPIBR-Bioinformatics/CodonUsage>. ([@bib2]; copy archived at <https://github.com/elifesciences-publications/MPIBR-Bioinformatics-CodonUsage>).

ddPCR {#s4-13}
-----

RNA was isolated from crude lysates or ribosomal fractions with QIAzol, following the manufacturer's instructions. 2--4 ng of RNA were treated with 4 units of DNAse for 20 min at 37°C and inactivated for 15 min at 75°C. The RNA was converted to cDNA using SuperScript IV (ThermoFisher) with a mixture of Random primers and dT15V primers. 1 µl out of 10 µl of the resulting cDNA was used for ddPCR (Bio-rad) with Taqman probes (Integrated DNA Technologies; see key Resources table for the sequences) following the manufacturer's instructions. The specificity of the primers for the HA-tagged versions of HRI was confirmed by ddPCRs in non-transfected neurons. The mRNA counts of each gene were normalized to the rRNA content of the corresponding fraction (ddPCR for rRNA was performed with cDNA diluted 1:10000). The normalized mRNA content of the fractions 7 to 11 (polysome) was related to the fractions 2--4 (monosome) with the following formula: (mRNA polysome)/(mRNA monosome + mRNA polysome) The disome was excluded from the calculations as its role in mRNA translation is not clear.

In vitro degradation assay {#s4-14}
--------------------------

200 ng of recombinant HRI (SignalChem) or 500 ng of recombinant eIF2α (abcam) were incubated with 2 µg of purified 20S proteasome (Enzo) in 20 mM Hepes pH 7.4/2 mM EDTA/1 mM EGTA for the indicated times at 37°C. When indicated, the 20S proteasome was incubated with 10uM MG132 for 30 min prior to its incubation with the kinase. Protein mixtures were loaded onto SDS-PAGE gels and stained o.n. with SYPRO Ruby Protein Gel Stain as indicated by the vendor. Gels were imaged using Gel Doc XR (Bio-Rad). In the figure the relative degradation of HRI+20S to HRI+20S+PI is shown.

Pharmacological treatments {#s4-15}
--------------------------

Proteasome inhibitors MG132 and Lactacystin were purchased from Sigma, dissolved in DMSO and used from 10 to 25 µM as indicated, unless otherwise indicated the inhibitor used in the experiments was MG132. Porphyrins were dissolved in DMSO and purchased from Millipore (CoPPIX), Sigma (FePPIX or hemin), or Cayman (SnMPIX and ZnPPIX), 4, 6 or 12 µM of each porphyrin was tested. In the figures always the 4 µM dosage is shown. Porphyrins were added at the same time as the proteasome inhibitors. NO inhibitors were added 1 hr before proteasome inhibitors and kept during the proteasome inhibitor treatment. L-NMMA (NG mono methyl L-Arginine, Cayman) was dissolved in water and used at 2 and 6 mM. 7-Nitroindazole (7-Ni, Sigma) was dissolved in DMSO and used at 100 and 200 µM. N-Omega-Nitro-L-Arginine (L-NNA, Sigma) was dissolved in water and used at 100 and 200 µM. S-methyl-L-thiocitrulline (L-SMTC, Sigma) was dissolved in water and used at 10 and 50 µM. ROS inhibitors were added 1 hr before proteasome inhibitor and kept during the proteasome inhibitor treatment; N-acetyl-cysteine (NAC, Sigma) was dissolved in water and used at 1 and 5 mM. Ascorbic Acid (AA, Sigma) was dissolved in water and used at 200 µM and 500 µM. MitoTempo (Sigma) was dissolved in water and used at 10 and 25 µM. Trolox (Sigma) was dissolved in DMSO and used at 500 µM and 1 mM. The PKR inhibitor ([@bib71]; [@bib52]) (Cayman) was dissolved in DMSO and used at a final concentration of 1 µM and was added 1 hr before proteasome inhibitor treatment. Protein synthesis was evaluated for all drugs alone and no differences were observed when compared to the control treated samples (data not shown; except for MG-132 and lactacystin). All experiments and dosages were tested in at least two biological replicates; the presented quantifications are from the higher dosage tested. Actinomycin-D (Sigma) was dissolved in DMSO and used at 10 µM. It was added at the same time as the PI when indicated.

Amino acid measurements {#s4-16}
-----------------------

1 million neurons (control, or following 30 min or 60 min MG132 20 µM treatment) were collected in 10% SSA (sulfosalicylic acid), centrifuged at maximum speed for 10 min and sent to Zurich ETH Zurich/University of Zurich (Functional Genomics Center), for free amino acid analysis measured by reverse phase HPLC.

Heme measurements {#s4-17}
-----------------

Hippocampal neurons were grown in 10 cm dishes (5 million cells per well), each plate was lysed in 50 μl of the buffer kinase buffer (5 mM MOPS, 2.5 mM β-glycerophosphate, 1 mM EGTA, 0,5 mM EDTA). The mouse hippocampus was lysed in 200 μl of the above buffer. Mouse blood was collected with 3 mM EDTA, the sample was centrifuged 5 min at 1000 rpm to collect the erythrocytes, the cells were extensively washed in PBS, and lysed with kinase buffer. Equal amounts of protein (measured by BCA assay -Pierce) were used for free heme measurement following the manufacturer's instructions (Sigma MAK-036).

HRI activity in the presence of blood and hippocampal lysates {#s4-18}
-------------------------------------------------------------

Blood and hippocampal lysates were obtained as indicated above. To inhibit the endogenous kinases and proteases, the lysates were heated at 60°C for 10 min, and centrifuged, 25 μg of the lysates were added to the kinase reaction mix (per reaction: 0.5 μg of recombinant eIF2α, 0.0005--0.001-0.0033--0.0066 μg of recombinant HRI, and 60 μM ATPγ). The reactions were carried out for 45 min at 30°C, stopped with SDS-Page running buffer, run on a gel and transferred to a PVDF membrane that was exposed to a phosphorimager screen.

Imaging immunocytochemistry and FISH {#s4-19}
------------------------------------

Images were acquired with a LSM780 confocal microscope (Zeiss) using 20x or 40x objectives (Plan Apochromat 20 x/NA 0.8 M27, Plan Apochromat 40 x/NA 1.4 oil DIC M27). Images were acquired in eight bit mode as Z-stacks with 1024 × 1024 pixels xy resolution through the entire thickness of the cell with optimal overlap of optical z-sections. The detector gain in the signal channel(s) was set to cover the full dynamic range but to avoid saturated pixels. Imaging conditions were held constant within an experiment.

Image analysis and representation {#s4-20}
---------------------------------

To quantify puromycin or HA immunoreactivity or ZsGreen fluorescence, three channel maximum intensity projections of the Z-stacks created in the Zeiss Zen software were opened in ImageJ. For single soma analyses all neuronal cell bodies in the image were manually outlined based on Map2 staining (to distinguish from glial cells) and areas saved as ROIs. Hela cell ROIs were outlined based on combined channels selecting a region around the nuclear stain. The image was split into single channel images in ImageJ and the mean grey value for each ROI was measured in the relevant channels. For visualization, maximum intensity projections of the Z-stacks were adjusted for brightness and contrast in ImageJ with the same settings for samples and controls and over the whole presented image. Examples of single dendrites shown were created with the ImageJ Plugin 'Straighten' by tracing a dendrite starting from the soma, resulting in left to right in the image representing proximal to distal.

Polysome profiling {#s4-21}
------------------

Cytosolic lysates from primary neuronal cultures were prepared as follows: Cell treated with vehicle or proteasome inhibitors were incubated with 100 μg/ml cycloheximide in the medium for 5 min, washed in cold PBS with 100 μg/ml cycloheximide and lysed in 8% glycerol, 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 100 μg/ml cycloheximide, 1 mM DTT, 1% Triton X-100, 24 U/ml TURBO DNase, 200 U/mL RNasin(R) Plus RNase Inhibitor. Lysates were pipetted up and down until homogenization was clear with a 0.4 × 20 mm needle (HSW FINE-JECT) on ice. Lysates were centrifuged for 10 min at 10,000 g at 4°C, and the supernatants were used for ribosome fractionation.

For sucrose gradients, all solutions were prepared in gradient buffer (20 mM Tris pH 7.5, 8% glycerol, 150 mM NaCl, 5 mM MgCl~2~, 100 μg/ml cycloheximide, 1 mM DTT). Gradients were prepared by sequentially adding different sucrose concentrations (in order from first added to last, 8 mL of 55%, 0.5 mL of 50%, 0.5 mL of 40%, 0.5 mL of 30%, 0.5 mL of 20%, 0.5 mL of 10%) into the same Thinwall polypropylene tube (Beckman). After the addition of each sucrose solution, tubes were placed at −80°C to freeze the content before the next layer. The gradients were stored at −80°C and left for equilibration at 4°C o.n. Then 0.5 to 1.5 OD (measured with NanoDrop at 260 nm) of the lysates were loaded on top of the gradients and spun at 36,000 rpm at 4°C for 2 hr with a SW41-Ti rotor (Beckman). Fractions from each sample were collected every 9 s using a density gradient fractionation system (Teledyne Isco, intensity used 1), chased by 60% sucrose 10% glycerol in water at 850 µL/min, and continuous monitoring at 254 nm using a UA-6 detector. For quantification of monosome and polysomes peaks, the area under the curve was measured using Image J or the following program: <https://software.scic.brain.mpg.de/projects/MPIBR/PolysomeProfiler>. The same script was used to visualize the overlay of the polysome profiles of different samples.

Statistics {#s4-22}
----------

Statistical significance of the quantification of IF and WB was tested from single or combined experiments (as stated in the figure legends). If multiple experiments were combined all the data are shown in the same plot. When necessary, data were normalized to one condition. Statistical analysis was performed using GraphPad Prism.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Little is known regarding the coordination of protein synthesis and protein degradation in neurons. This paper demonstrates that one of the four eIF2α kinases, heme-regulated kinase inhibitor, regulates the decrease in mRNA translation to restore proteostasis during inhibition of the ubiquitin proteasome inhibition system.

**Decision letter after peer review:**

Thank you for submitting your article \"Neuronal Proteostasis is mediated by the switch-like expression of Heme-regulated Kinase 1\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editor, and the evaluation has been overseen by Eve Marder as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Alvarez-Castelao et al. present an interesting feedback mechanism to decrease protein synthesis during ubiquitin-proteasome system (UPS) inhibition in neurons. Proteosome inhibition leads to decreased mRNA translation in both neuronal soma and dendrites that was accompanied by eIF2α phosphorylation. Knockout of heme-regulated kinase inhibitor (HRI), but not the other 3 eIF2α kinases, resulted in reduced inhibition of protein synthesis and eIF2α phosphorylation during UPS inhibition. The authors show that basal levels of HRI are low, but increase after UPS inhibition. They propose that the endogenous level of HRI is very low due to degradation by the proteasome. They further suggest that there is also translational regulation of HRI which is due to rare codons in its CDS. Finally, they suggest that the kinase activity of HRI is constitutively high due to low heme levels in neurons.

Essential revisions:

1\) It\'s unexpected and interesting that HRI would be the eIF2α kinase mediating the ISR response in neurons on inhibition of the proteasome. However, it\'s difficult to accept that only a \~30-40% increase in HRI protein levels is enough to account for the inhibition of bulk protein synthesis by 60 to \>90% elicited by PI treatments in different experiments without some other mechanism for activating HRI kinase function, as there are low heme levels regardless of whether or not the proteasome is inhibited. Indeed, there are published results describing mechanisms for controlling HRI activity through dimerization and domain interactions. They should assay the level of phosphorylation of Threonine-485 in HRI, a known site of autophosphorylation in the activation loop and indicator of HRI kinase activity, to determine whether it increases substantially more on PI treatment than the modest 1.3-fold increase seen in HRI protein levels. Alternatively, they could try to show that only a \< 2-fold increase in HRI expression in untreated neurons would be sufficient to mimic the effects of PI on eIF2α phosphorylation and general translation, as their model predicts. They show in Figure 6D-E that HRI overexpression has this effect, but do not quantify the extent of overexpression above the native levels.

2\) A major branch of the ISR entails the translational activation of transcription factors, notably ATF4, by a re-initiation mechanism involving uORFs, and it is surprising that they have generally ignored this aspect of the response in their experiments, with only one experiment in Figure 5---figure supplement 1A showing increased polysome association of ATF4 mRNA on PI treatment. Given that the quality of the Western blots used to quantify eIF2α phosphorylation is not very high, and the multiple WB quantifications of peIF2α and unphosphorylated eIF2α needed to determine ratios of peIF2α:total eIF2α, it would be very reassuring to show that polysome association of ATF4 mRNA, or expression of an ATF4 reporter, increases on PI treatment of WT but not of HRI KO cells. Alternatively, qRT-PCR for ATF4 targets could be performed under various conditions.

3\) There are a number of experiments in which treatments are found not to affect the translational response to PI, but no controls are presented for these negative results to convince us that the treatments had the intended effects in their hands, on their cells. In other cases, controls are lacking to establish the specificities of phospho-specific antibodies, or to show that they achieved a clean separation of dendrites from cell bodies. These controls have to be included for the results to be interpretable. These include the following:

-- Controls are required to document that the dendrite preparation in Figure 1H is not contaminated with cell bodies.

-- The experiment in Figure 2---figure supplement 1 should be described explicitly in the text of Results, and controls are required to document that actinomycin treatment successfully blocked transcription.

-- For Figure 2---figure supplement 1C, controls are required to document the specificity of the phospho-specific antibodies and the ability to observe changes in phosphorylation using them in response to, eg. rapamycin treatment of their cell lines.

-- For Figure 3A, it is necessary to indicate the nature of the PKR inhibitor and to document that it was effective at inhibiting PKR activity in the neurons.

-- Controls are lacking for the experiments in Figure 5---figure supplement 2 to assure us that the treatments used to quench ROS, block NO synthesis were effective in their cells/hands. The same goes for the heme oxygenase inhibitors; although in this case, the logic of the experiment also appears to be flawed, as inhibitors of heme breakdown should lead to higher, not lower, heme levels and thus prevent, not elicit, HRI activation.

4\) The results in Figure 6B could be explained differently by proposing that the hippocampal lysate has lower levels of peIF2α phosphatase. This alternative explanation could be ruled out by incubating peIF2α in each lysate (without added HRI) and measuring rates of dephosphorylation over time. Alternatively, they could show that similar levels of peIF2α are produced in both lysates when Gcn2, PERK or PKR are added instead of HRI.

-- What was the loading control used for Figure 4A and 4B quantifications? Also there are no loading controls for the representative western shown in Figure 4---figure supplement 1D.

5\) The results in Figure 5---figure supplement 1C contradict the claim that codon optimization increases polysome association of HRI-HA mRNA claimed from the data in Figure 5---figure supplement 1B, as the wt and opt mRNAs show the same polysome association in control conditions in Figure 5---figure supplement 1C. This discrepancy needs to be addressed in the text.

6\) Regarding Figure 6C, it should be verified that hemin does not stimulate protein synthesis when added to HRI KO cells treated with PI; and that hemin addition suppresses the increase in peIF2α elicited by PI.

7\) The statement in the Discussion that the data indicate, among other findings, that \"iii) the initial decrease in general translation leads to an increase in the availability of rare codons (Saikia et al., 2016), further increasing the translation of HRI mRNA\" is a plausible scenario but in no way demonstrated by the data. Also, I\'m not sure what they mean by availability of rare codons-probably they mean the cognate tRNAs for such codons.

8\) Related to point 1, the statements in the Discussion \"Our data indicate that above multiple mechanisms cleverly cooperate to enhance the activity and expression of HRI in response to reduced proteasome activity. These mechanisms make HRI an optimized sensor and effector for sensing and responding to proteasome inhibition.\" seem premature, as they have identified no mechanism for enhancing HRI activity, although one might well exist that remains to be uncovered, and document only a small increase in HRI expression which may or may not be adequate to explain the observed translational responses.

9\) The authors examined HRI-HA expression in Figure 4E-G and found it much lower than the ZsGreen reporter expressed by the DOX-inducible bi-directional promoter. Is it possible that the HA tag destabilized HRI? Figure 4F-G: It is not specified how long the Doxycycline treatment was -- this should be added. The experiment could be repeated treating with Doxycycline for 1 h to test whether the short half-life of HRI contributes to the lack of detection. Is it possible that there is directionality of the promoter in this situation (i.e., were the cDNAs switched relative to the promoter to see if similar results were obtained?

10\) Figure 4---figure supplement 1B: The loading control is missing and should be added. The figure legend states that the related analysis is in Figure 4D -- do the authors mean Figure 4B? It would be clearer to move the representative image (Figure 4---figure supplement 1B) close by its related plot (Figure 4B?).

11\) Figure 4---figure supplement 1E: The plot should show also the quantification of the condition \"+ PI\".

12\) Figure 5---figure supplement 2H: Statistical analyses between the PI and the PI+ hemin conditions are missing. Figure 5---figure supplement 2H does not seem to be referenced in the manuscript. It is unclear whether Figure 5---figure supplement 2H and Figure 6C are the same experiment? If redundant, it should be removed.

13\) Related to point 1, the statements in the Discussion \"Our data indicate that above multiple mechanisms cleverly cooperate to enhance the activity and expression of HRI in response to reduced proteasome activity. These mechanisms make HRI an optimized sensor and effector for sensing and responding to proteasome inhibition.\" seem premature, as they have identified no mechanism for enhancing HRI activity, although one might well exist that remains to be uncovered, and document only a small increase in HRI expression which may or may not be adequate to explain the observed translational responses.

14\) In addition to protein expression, does hemin also rescue eIF2α phosphorylation increases in PI conditions?

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"The switch-like expression of Heme-regulated kinase 1 mediates neuronal proteostasis following proteasome inhibition\" for further consideration by *eLife*. Your revised article has been evaluated by Timothy Behrens (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed it before acceptance. These largely include changes to the text including adding citations, and inclusion of data as a supplemental figure and are outlined by reviewer 3 below.

Reviewer \#2:

The authors have addressed my comments well. The revised manuscript presents a biologically significant set of findings that bring novel insights into proteostasis during proteasome inhibition and, in my view, is very worthy of publication.

Reviewer \#3:

The revised paper has been improved and the additional information provided in the rebuttal serve adequately to allay my major concerns. There are however some additional revisions to the text that should be made to improve the quality of the report, as described below:

Essential Revision point 1. Regarding the data provided in the rebuttal and described as \"Below we plot our imaging data (from Figure 4E-G of the original and revised manuscript) measuring the level of HRI expression (using a transfected construct) and the corresponding nascent protein signal (obtained using brief puromycin labeling) in the same neurons. As expected, \[....\]. Consequently, it is possible that a 30% increase in HRI expression decreases protein synthesis by more than 50%.\" These new experimental data and analysis should be provided in a supplementary figure and summarized in the Results to bolster the key conclusion that only a 30% increase in HRI expression could potentially decrease protein synthesis by more than 50%.

Essential Revision point 3: the controls provided for the reviewer\'s benefit should be included as supplementary data, as they will be valuable for all readers of the paper. Note however that the control data provided to validate the antibodies against phosphorylated 4EBP are hard to evaluate. Should all of the phosphorylated isoforms be reduced equally by rapamycin? Also, an immunofluorescence assay was provided that was labeled incorrectly as an immunoblot and is difficult to evaluate without quantification and explanation. They should cite the literature justifying the use of the PKR inhibitor without confirming its efficacy in their hands/cells.

Essential Revision point 4: The legend to Figure 6B should be modified to reflect the use of heat inactivated extracts. Also, the conditions for the assays with purified components should be included in the Materials and methods, and the legend to Figure 6A should indicate the use and concentration of purified components. The legends to Figure 4A-B should be revised to indicate the method for normalization of the data (Figure 4A) and to indicate that co-immunoprecipited samples were quantified (Figure 4B).

Essential Revision point 7: The sentence in the Discussion was modified, but it would be even more accurate to say that the availability of charged tRNAs was being altered, to distinguish this from alterations in tRNA abundance which would be unexpected. Also, in the Abstract it\'d be more correct to state \"Following proteasome inhibition, HRI protein levels increase owing to stabilization of HRI and enhanced translation presumably via the increased availability of charged tRNAs for its rare codons.\"
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Author response

> Essential revisions:
>
> 1\) It\'s unexpected and interesting that HRI would be the eIF2α kinase mediating the ISR response in neurons on inhibition of the proteasome. However, it\'s difficult to accept that only a \~30-40% increase in HRI protein levels is enough to account for the inhibition of bulk protein synthesis by 60 to \>90% elicited by PI treatments in different experiments without some other mechanism for activating HRI kinase function, as there are low heme levels regardless of whether or not the proteasome is inhibited. Indeed, there are published results describing mechanisms for controlling HRI activity through dimerization and domain interactions. They should assay the level of phosphorylation of Threonine-485 in HRI, a known site of autophosphorylation in the activation loop and indicator of HRI kinase activity, to determine whether it increases substantially more on PI treatment than the modest 1.3-fold increase seen in HRI protein levels.

We agree that there are mechanisms besides heme reduction capable of changing the HRI activity, we have tested most of the mechanisms described thus far and found no effect on the translational response mediated by HRI activity in our experimental system.

Unfortunately, it is not possible to check HRI threonine-485 phosphorylation in neurons due to the very low expression of HRI, and the lack of good antibodies. In liver and blood, where HRI has been studied more extensively, the high HRI protein levels make it much easier to study and we can detect the hyperphosphorylated version in blood ourselves (see Figure 4---figure supplement 1B). The study of this modification by mass spectrometry is also not possible because we failed to identify HRI by MS. We must emphasize that a 1.3 fold increase in an active kinase cannot be qualified as modest, for example the specific activity of recombinant HRI is exponentially related to the amount of protein until it gets saturated (see for example the specific activity assay for the purified HRI from Sigma-Aldrich (<https://www.sigmaaldrich.com/catalog/product/sigma/srp5321?lang=es&region=ES&gclid=EAIaIQobChMIyITW2e6N6QIVR9HeCh1aXArbEAAYASAAEgLOdfD_BwE>).

Importantly, in cells eIF2B levels are limiting, for this reason partial eIF2α phosphorylation in vivo is able to fully repress eIF2B function and protein synthesis initiation (Adomavicius et al., 2019).

> Alternatively, they could try to show that only a \< 2-fold increase in HRI expression in untreated neurons would be sufficient to mimic the effects of PI on eIF2α phosphorylation and general translation, as their model predicts. They show in Figure 6D-E that HRI overexpression has this effect, but do not quantify the extent of overexpression above the native levels.

Thanks for this suggestion- we see that it is worthwhile to really explain how small changes in kinase activity can have a big effect on global protein synthesis levels. We plot our imaging data (from figure 4E-G of the original and revised manuscript) measuring the level of HRI expression (using a transfected construct) and the corresponding nascent protein signal (obtained using brief puromycin labeling) in the same neurons. As expected, the correlation between the expression of HRI kinase and the inhibition in protein synthesis is not linear, the best fit corresponds to a power line. This is consistent with the assumption that one molecule of HRI will lead to the phosphorylation of multiple molecules of substrate. Resulting from this form of dependence, small increases in HRI expression will exert most impact on protein synthesis within a low to intermediate range: when expression is not too low to impact eIF2α phosphorylation, but also not too high because then already most protein synthesis is shut off. Consequently, it is possible that a 30% increase in HRI expression decreases protein synthesis by more than 50%.

> 2\) A major branch of the ISR entails the translational activation of transcription factors, notably ATF4, by a re-initiation mechanism involving uORFs, and it is surprising that they have generally ignored this aspect of the response in their experiments, with only one experiment in Figure 5---figure supplement 1A showing increased polysome association of ATF4 mRNA on PI treatment. Given that the quality of the Western blots used to quantify eIF2α phosphorylation is not very high, and the multiple WB quantifications of peIF2α and unphosphorylated eIF2α needed to determine ratios of peIF2α:total eIF2α, it would be very reassuring to show that polysome association of ATF4 mRNA, or expression of an ATF4 reporter, increases on PI treatment of WT but not of HRI KO cells. Alternatively, qRT-PCR for ATF4 targets could be performed under various conditions.

We are a bit stung by the criticism that the Western Blot quality is not high- this was an extremely challenging experiment. eIF2α phosphorylation is very labile- despite this, we obtained well defined bands, and we always loaded in the same gel biological replicates, in addition to the experimental replicates. We don't think that ATF4 is a good additional readout, because other pathways can activate its translation, for example mTOR (Park et al., 2017) and the ATF4 protein is itself degraded by the proteasome (Lassot et al., 2001). The ratio of eIF2α vs peIF2α is the most accurate way to measure peIF2α changes, whereas measuring ATF4 or its target genes is indirect and can lead to misleading conclusions.

> 3\) There are a number of experiments in which treatments are found not to affect the translational response to PI, but no controls are presented for these negative results to convince us that the treatments had the intended effects in their hands, on their cells. In other cases, controls are lacking to establish the specificities of phospho-specific antibodies, or to show that they achieved a clean separation of dendrites from cell bodies. These controls have to be included for the results to be interpretable. These include the following:
>
> -- Controls are required to document that the dendrite preparation in Figure 1H is not contaminated with cell bodies.

We prepare neuronal cultures on these filters routinely in the laboratory, and we perform several tests to prove the quality of the separation of the neuronal compartments, which is always very good. We now refer in the revised manuscript to our recent publication (Biever et al., 2020) (see Figure S1H which illustrates the quality of the separation). In addition, the [Author response image 1](#sa2fig1){ref-type="fig"} shows that Lamin B1 a protein confined to the neuronal somata is indeed mainly found in the cell material on the upper surface of the filters.

![Western Immunoblot for Lamin B1.\
Neurons were scraped from the upper and lower part of the membrane and the nuclear protein Lamin B1 was detected by Western Blot.](elife-52714-resp-fig1){#sa2fig1}

> -- The experiment in Figure 2---figure supplement 1 should be described explicitly in the text of the Results, and controls are required to document that actinomycin treatment successfully blocked transcription.

We performed an experiment and prepared [Author response image 2](#sa2fig2){ref-type="fig"} for the reviewers which shows that ActD works as expected in our experimental system but did not include it into the revised manuscript.

![Testing actinomycin D's effectiveness in blocking transcription using ddPCR of Arc mRNA.\
Neurons were treated with ActD for 2h and mRNA levels of Arc, an immediate early gene, in non-treated and treated neurons were measured. In the left graph the ddPCR counts for Arc mRNA and ERCC (used for normalization) are shown. Treatment with actinomycin D (indicated by "+") completely prevented the transcription of Arc mRNA. In the right graph, the average of the experiments normalized to the ERCC standards are shown.](elife-52714-resp-fig2){#sa2fig2}

> -- For Figure 2---figure supplement 1C, controls are required to document the specificity of the phospho-specific antibodies and the ability to observe changes in phosphorylation using them in response to, eg. rapamycin treatment of their cell lines.

We do not use cell lines but primary neurons for our experiments. The phospho-specific antibodies used for this paper were already tested using Rapamycin by the commercial supplier (see Cell-Signaling website for the different antibodies; peIF4G- <https://www.cellsignal.com/products/primary-antibodies/phospho-eif4g-ser1108-antibody/2441?site-search-type=Products>; p4EBP- <https://www.cellsignal.com/products/primary-antibodies/phospho-4e-bp1-thr37-46-236b4-rabbit-mab/2855?site-search-type=Products>; peIF4B- <https://www.cellsignal.com/products/primary-antibodies/phospho-eif4b-ser406-d1c10-rabbit-mab/8151?site-search-type=Products>) and are widely used by research groups in the field. Nevertheless, we treated neurons with Rapamycin for 2h and confirmed the specificity of the antibodies (see [Author response image 3](#sa2fig3){ref-type="fig"}).

![Western Immunoblot for phosphorylated translation factors.\
Neurons were treated with Rapamycin (10 µm) for 2h and the phosphorylation of 4EBP1, EIF4G and EIF4B was detected by Western Blot using the phospho-specific antibodies described in the paper. A decrease in the phosphorylation of the proteins in response to Rapamycin treatment was observed.](elife-52714-resp-fig3){#sa2fig3}

> -- For Figure 3A, it is necessary to indicate the nature of the PKR inhibitor and to document that it was effective at inhibiting PKR activity in the neurons.

The PKR Inhibitor is an oxindole/imidazole derivative that binds the ATP-binding site of PKR and blocks autophosphorylation with an IC50 value of 186-210 nM (Zhu et al., 2011). We used a concentration of 1µM for 4h. The inhibitor is so powerful that it even works in vivo by intraperitoneal administration reducing the phosphorylation of PKR and eIF2α in the brain (Ingrand et al., 2007). Similar administration in mice enhances long-term memory storage, including contextual and auditory long-term fear memories (Zhu et al., 2011). Given the profound effect of the HRI KO on protein synthesis levels after brief proteasome inhibition, it is clear that HRI is the primary kinase activated in response to brief proteasome inhibition in our experiments. Of course, we cannot rule out the idea that other kinases could also contribute to eIF2α phosphorylation during prolonged proteasome inhibition, for example. Indeed, we include mention of this possibility in our Discussion.

> -- Controls are lacking for the experiments in Figure 5---figure supplement 2 to assure us that the treatments used to quench ROS, block NO synthesis were effective in their cells/hands. The same goes for the heme oxygenase inhibitors; although in this case, the logic of the experiment also appears to be flawed, as inhibitors of heme breakdown should lead to higher, not lower, heme levels and thus prevent, not elicit, HRI activation.

A useful and robust pharmacological strategy for testing whether a particular pathway is involved in a cellular process is the use of several different inhibitors. This is the approach we have taken. We used several (3 different ROS quenchers, 4 different NOS inhibitors and 3 different HO inhibitors) chemically distinct well-characterized inhibitors (used in hundreds of published studies) acting on the same pathway, and several dosages (data not shown) of each of these inhibitors. It is extremely unlikely that none of the drugs were working at any tested dosage. Additionally, we have measured ROS and NO species directly and we failed to detect any changes after proteasome inhibition (data not shown). We note that the direct measurement of Heme Oxygenase activity is extremely complicated and has low sensitivity and therefore especially challenging in primary cultured neurons. We don't believe the logic of our Heme oxygenase inhibitor experiment is flawed. In fact, we were looking for an inhibition of HRI activity using the heme breakdown inhibitors. The rationale for the use of Heme oxygenase inhibitors was to test the possibility that proteasome inhibition could activate Heme breakdown, via activation of the Heme oxygenase. We thus used the HO inhibitors as a tool to block heme breakdown and block any resulting activation of HRI. We did not observe any rescue of protein synthesis inhibition when any of the HO inhibitors were added together with the proteasome inhibitor, thus we can conclude that heme breakdown mediated by heme oxygenase does not participate in the global downregulation of protein synthesis.

> 4\) The results in Figure 6B could be explained differently by proposing that the hippocampal lysate has lower levels of peIF2α phosphatase. This alternative explanation could be ruled out by incubating peIF2α in each lysate (without added HRI) and measuring rates of dephosphorylation over time. Alternatively, they could show that similar levels of peIF2α are produced in both lysates when Gcn2, PERK or PKR are added instead of HRI.

Yes, we agree with the idea the reviewer presents. Indeed, to avoid artifacts due to other enzymatic activities than the one we were analyzing (HRI activity), all the enzymatic activities from the lysate were inactivated by denaturation (heating up the samples as indicated in the Materials and methods section). The cleared lysates thus contained only soluble material such as free Heme prior to adding the purified HRI and eIF2α to the lysates to perform the activity assay.

> -- What was the loading control used for Figure 4 a and 4B quantifications? Also there are no loading controls for the representative western shown in Figure 4---figure supplement 1D.

Figure 4A is a ddPCR experiment where levels of HRI were normalized to ribosomal RNA. The experiments represented in Figure 4B and Figure 3---figure supplement 1D are immunoprecipitation experiments. In these experiments, one specific antibody is used to isolate (pull-down) the protein of interest (POI). The POI remains bound to the antibody- the antibody is bound to a physical support such as magnetic beads. The beads+antibody are used as bait to isolate the POI from the rest of the proteins of the tissue. The beads+antibody+POI are loaded onto a gel with the aim of quantifying the amount of protein present in the lysate. The nature of the technique makes it not suitable for loading controls, as other proteins (different from the POI) that could serve as "loading controls" will be in the immunoprecipitates owing to non-specific binding to the beads or to the antibody, consequently its presence in the lysate is non-specific and potentially variable and hence cannot be used for quantification. The way to make IPs semi-quantitative is repeating them several times (and of course loading the same amount of total protein to each IP by measuring the protein used for the input by an accurate method- in our case QBIT). The data represented in the figure come from 4 independent experiments, each of them was performed with 6 separate dishes of neurons. Additionally, we present a negative control IP from the HRI knockout neurons. The IPs are done with an excess of the antibody (we calculated the amount of antibody necessary by titration experiments), to ensure the precipitation of the total amount of endogenous HRI and prevent saturation of the antibody.

We did this experiment by IP, because we cannot detect HRI in the intact lysates. In addition, the increased HRI expression demonstrated by the IP experiments is supported by the measurement of the translation rates of HRI by ddPCR and Polysome Profiling, and by the experiment demonstrating that HRI is degraded by the proteasome. Both processes contribute to the increase in expression of HRI shown by the IP experiments.

> 5\) The results in Figure 5---figure supplement 1C contradict the claim that codon optimization increases polysome association of HRI-HA mRNA claimed from the data in Figure 5---figure supplement 1B, as the wt and opt mRNAs show the same polysome association in control conditions in Figure 5---figure supplement 1C. This discrepancy needs to be addressed in the text.

There is no discrepancy. Please note that the normalization in the two graphs is different to emphasize different findings from the same experiment. In the Figure 5---figure supplement 1B we show the higher association to the polysomes of the optimized HRI mRNA in control conditions, and in the Figure 5---figure supplement 1C the change in the behavior of the optimized HRI mRNA in comparison to the nonoptimized HRI mRNA after proteasome inhibition, for this reason both control conditions have the value of 1. To make the figure easier to interpret we have now split Figure 5---figure supplement 1C in two graphs and added a description to the legend on how the normalization was conducted.

> 6\) Regarding Figure 6C, it should be verified that hemin does not stimulate protein synthesis when added to HRI KO cells treated with PI; and that hemin addition suppresses the increase in peIF2α elicited by PI.

The reviewer is concerned about potential off-target effects of hemin in the absence of HRI. To address this, we added hemin to HRI KO primary neurons. We did not observe significant changes in basal protein synthesis due to the addition of hemin (Figure 5---figure supplement 1 I-J). Furthermore, the addition of hemin+PI in wt neurons (expressing HRI that can actually respond to heme), showed a significant reduction of the phosphorylation of eIF2α (Figure 5---figure supplement 1 K-L), but not a complete blockade. This is consistent with the results shown in the HRI KO neurons for eIF2α phosphorylation (Figure 3F), and translation (Figure 3C).

> 7\) The statement in the Discussion that the data indicate, among other findings, that \"iii) the initial decrease in general translation leads to an increase in the availability of rare codons (Saikia et al., 2016), further increasing the translation of HRI mRNA\" is a plausible scenario but in no way demonstrated by the data. Also, I\'m not sure what they mean by availability of rare codons-probably they mean the cognate tRNAs for such codons.

We have changed this sentence.

> 8\) Related to point 1, the statements in the Discussion \"Our data indicate that above multiple mechanisms cleverly cooperate to enhance the activity and expression of HRI in response to reduced proteasome activity. These mechanisms make HRI an optimized sensor and effector for sensing and responding to proteasome inhibition.\" seem premature, as they have identified no mechanism for enhancing HRI activity, although one might well exist that remains to be uncovered, and document only a small increase in HRI expression which may or may not be adequate to explain the observed translational responses.

We disagree. We have identified a mechanism for enhancing the activity of HRI- by increasing its expression. We show that in neurons heme levels are very low, leading to a constitutive activation of the kinase. We have now changed this line to indicate "enhance the expression and activity".

> 9\) The authors examined HRI-HA expression in Figure 4E-G and found it much lower than the ZsGreen reporter expressed by the DOX-inducible bi-directional promoter. Is it possible that the HA tag destabilized HRI? Figure 4F-G: It is not specified how long the Doxycycline treatment was -- this should be added. The experiment could be repeated treating with Doxycycline for 1 h to test whether the short half-life of HRI contributes to the lack of detection. Is it possible that there is directionality of the promoter in this situation (i.e., were the cDNAs switched relative to the promoter to see if similar results were obtained?

We agree with the reviewer that sometimes adding a tag to a protein and the position of the tag can change its half-life. In our initial experiments we tried several different induction times with Doxycycline with the original construct carrying ZsGreen and HRI-HA on the same plasmid. We never saw measurable amounts of HRI-HA expression and we set out to investigate the reviewers' question. Instead of switching the order relative to the promoter we 1) placed the cDNAs on two different plasmids (to lower the amount of ZsGreen and to carry out controls without ZsGreen expression), 2) compared the expression with the HA tag placed on the N-terminus vs attachment to the C-terminus and 3) compared codon-optimized versions of both N- and C-terminally tagged HRI with the wild-type non-optimized tagged HRI.

From these experiments we were able to draw the following conclusions:

With the codon-optimized tagged versions of HRI we obtained measurable expression with long (16-24 h) Dox induction (e.g. data shown in Figure 5E-G). The resulting protein from the codon-optimized version is identical to the protein from the wild-type non-optimized version therefore destabilization by the HA tag can't be a major explanation for the difficulty to express HRI without the tag. Rather the codon-usage in the wild-type sequence plays a major role.

Furthermore, we investigated the influence of the degradational component on HRI expression by short time (2hr) induction of either C-terminally or N-terminally tagged HRI expression in absence or presence of MG132 (see [Author response image 4](#sa2fig4){ref-type="fig"}). Proteasome inhibition increases (in accordance with our model that HRI is a proteasome substrate) the expression levels of both N- and C-terminally tagged HRI to a roughly equal extent (see [Author response image 4](#sa2fig4){ref-type="fig"}).

![Expression of transfected HRI in primary neurons -/+ proteasome inhibition, after short induction with Doxycycline (2h).\
Left panel shows the expression of HRI tagged on the N- terminus, and the right panel shows the expression of HRI tagged on the C-terminus. HRI expression was measured by Immunofluorescence using the HA tag. tf = transfected, PI = proteasome inhibitor.](elife-52714-resp-fig4){#sa2fig4}

Taken together, the experiments confirm our two proposed mechanisms to keep HRI protein levels low in neurons: suboptimal translation rapid degradation by the proteasome and reduced synthesis, due at least impart to codon nonoptimality.

Although we never observed significant expression of HRI construct (above background levels- see [Author response image 4](#sa2fig4){ref-type="fig"}) with 2h Doxycycline induction, we carried out the reviewer's requested experiment with 1h Doxycycline induction with the bidirectional expression plasmid. As expected, we did not observe measurable HRI-HA expression- it is simply too short of an induction for this particular protein.

> 10\) Figure 4---figure supplement 1B: The loading control is missing and should be added.

There is a loading control already in this figure. If the reviewer is referring to panel D and not B, please refer to the answer to this same question in point 4.

> The figure legend states that the related analysis is in Figure 4D -- do the authors mean Figure 4B?

We corrected this typo in the text.

> It would be clearer to move the representative image (Figure 4---figure supplement 1B) close by its related plot (Figure 4B?).

We prefer to leave this as is, the quantification is the most meaningful part of this specific experiment.

> 11\) Figure 4---figure supplement 1E: The plot should show also the quantification of the condition \"+ PI\".

This condition is already taken into account in the represented results, we have modified the figure legend to clarify this point.

> 12\) Figure 5---figure supplement 2H: Statistical analyses between the PI and the PI+ hemin conditions are missing. Figure 5---figure supplement 2H does not seem to be referenced in the manuscript. It is unclear whether Figure 5---figure supplement 2H and Figure 6C are the same experiment? If redundant, it should be removed.

The experiment in the Figure 6C was done by western blot and the one in Figure 5---figure supplement 2H was done in situ, we clarified this in the figure legends and added the missing figure reference in the text.

> 13\) Related to point 1, the statements in the Discussion \"Our data indicate that above multiple mechanisms cleverly cooperate to enhance the activity and expression of HRI in response to reduced proteasome activity. These mechanisms make HRI an optimized sensor and effector for sensing and responding to proteasome inhibition.\" seem premature, as they have identified no mechanism for enhancing HRI activity, although one might well exist that remains to be uncovered, and document only a small increase in HRI expression which may or may not be adequate to explain the observed translational responses.

Repeat of comment 8- see answer above.

> 14\) In addition to protein expression, does hemin also rescue eIF2α phosphorylation increases in PI conditions?

Repeat of comment 6-see answer above.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed it before acceptance. These largely include changes to the text including adding citations, and inclusion of data as a supplemental figure and are outlined by Reviewer 3 below.
>
> Reviewer \#3:
>
> The revised paper has been improved and the additional information provided in the rebuttal serve adequately to allay my major concerns. There are however some additional revisions to the text that should be made to improve the quality of the report, as described below:
>
> Essential Revision point 1. Regarding the data provided in the rebuttal and described as \"Below we plot our imaging data (from Figure 4E-G of the original and revised manuscript) measuring the level of HRI expression (using a transfected construct) and the corresponding nascent protein signal (obtained using brief puromycin labeling) in the same neurons. As expected, \[....\]. Consequently, it is possible that a 30% increase in HRI expression decreases protein synthesis by more than 50%.\" These new experimental data and analysis should be provided in a supplementary figure and summarized in the Results to bolster the key conclusion that only a 30% increase in HRI expression could potentially decrease protein synthesis by more than 50%.

We added a new supplementary figure (Figure 6---figure supplement 1).

> Essential Revision point 3: the controls provided for the reviewer\'s benefit should be included as supplementary data, as they will be valuable for all readers of the paper. Note however that the control data provided to validate the antibodies against phosphorylated 4EBP are hard to evaluate. Should all of the phosphorylated isoforms be reduced equally by rapamycin? Also, an immunofluorescence assay was provided that was labeled incorrectly as an immunoblot and is difficult to evaluate without quantification and explanation. They should cite the literature justifying the use of the PKR inhibitor without confirming its efficacy in their hands/cells.

We added a panel with the controls for the antibodies in the Figure 2---figure supplement 1. The 4EBP1 antibody has more than 700 references on the Cell Signaling web page, supporting its specificity. The 4EBP1 phosphorylated isoforms that can be detected depend on the type of gels that each lab runs. The best way to detect "all" the phosphorylated isoforms is to use a bi-dimensional gel, otherwise one can only see a global reduction in the phosphorylated isoforms as we show here. Additionally, we used an antibody that is specific for the phosphorylation of a specific Threonine, the co-occurrence of the phosphorylation in these positions with other phosphorylation sites is not within the scope of this paper. This antibody was chosen because it labels the most common phosphorylation positions in 4eBP1.

> Essential Revision point 4: The legend to Figure 6B should be modified to reflect the use of heat inactivated extracts. Also, the conditions for the assays with purified components should be included in the Materials and methods, and the legend to Figure 6A should indicate the use and concentration of purified components. The legends to Figure 4A-B should be revised to indicate the method for normalization of the data (Figure 4A) and to indicate that co-immunoprecipited samples were quantified (Figure 4B).

We modified the figure legends and the Materials and methods as requested.

> Essential Revision point 7: The sentence in the Discussion was modified, but it would be even more accurate to say that the availability of charged tRNAs was being altered, to distinguish this from alterations in tRNA abundance which would be unexpected. Also in the Abstract it\'d be more correct to state \"Following proteasome inhibition, HRI protein levels increase owing to stabilization of HRI and enhanced translation presumably via the increased availability of charged tRNAs for its rare codons.\"

We modified the Abstract. We added "charged tRNAs" in the Discussion section.

[^1]: Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Madrid, Spain.
